<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1305" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1305/" /><meta name="ncbi_pagename" content="Huntington Disease - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Huntington Disease - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Huntington Disease" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/07/05" /><meta name="citation_author" content="Nicholas S Caron" /><meta name="citation_author" content="Galen EB Wright" /><meta name="citation_author" content="Michael R Hayden" /><meta name="citation_pmid" content="20301482" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1305/" /><meta name="citation_keywords" content="Huntington Chorea" /><meta name="citation_keywords" content="Huntington Chorea" /><meta name="citation_keywords" content="Huntingtin" /><meta name="citation_keywords" content="HTT" /><meta name="citation_keywords" content="Huntington Disease" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Huntington Disease" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Nicholas S Caron" /><meta name="DC.Contributor" content="Galen EB Wright" /><meta name="DC.Contributor" content="Michael R Hayden" /><meta name="DC.Date" content="2018/07/05" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1305/" /><meta name="description" content="Huntington disease (HD) is a progressive disorder of motor, cognitive, and psychiatric disturbances. The mean age of onset is 35 to 44 years and the median survival time is 15 to 18 years after onset." /><meta name="og:title" content="Huntington Disease" /><meta name="og:type" content="book" /><meta name="og:description" content="Huntington disease (HD) is a progressive disorder of motor, cognitive, and psychiatric disturbances. The mean age of onset is 35 to 44 years and the median survival time is 15 to 18 years after onset." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1305/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/huntington/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1305/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CD30DE0401901000000000A4B038F.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1305_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1305_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/homocystinuria/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hd-l2/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1305_"><span class="title" itemprop="name">Huntington Disease</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Huntington Chorea</div><p class="contrib-group"><span itemprop="author">Nicholas S Caron</span>, PhD, <span itemprop="author">Galen EB Wright</span>, PhD, and <span itemprop="author">Michael R Hayden</span>, MB, ChB, PhD, FRCP(C), FRSC.</p><a data-jig="ncbitoggler" href="#__NBK1305_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1305_ai__"><div class="contrib half_rhythm"><span itemprop="author">Nicholas S Caron</span>, PhD<div class="affiliation small">Department of Medical Genetics<br />University of British Columbia<br />Vancouver, British Columbia, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.cbu.tmmc@noracn" class="oemail">ac.cbu.tmmc@noracn</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Galen EB Wright</span>, PhD<div class="affiliation small">Department of Medical Genetics<br />University of British Columbia<br />Vancouver, British Columbia, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.cbu.tmmc@thgirwg" class="oemail">ac.cbu.tmmc@thgirwg</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Michael R Hayden</span>, MB, ChB, PhD, FRCP(C), FRSC<div class="affiliation small">Department of Medical Genetics<br />University of British Columbia<br />Vancouver, British Columbia, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.cbu.tmmc@hrm" class="oemail">ac.cbu.tmmc@hrm</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">October 23, 1998</span>; Last Update: <span itemprop="dateModified">July 5, 2018</span>.</p><p><em>Estimated reading time: 42 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="huntington.Summary" itemprop="description"><h2 id="_huntington_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Huntington disease (HD) is a progressive disorder of motor, cognitive, and psychiatric disturbances. The mean age of onset is 35 to 44 years and the median survival time is 15 to 18 years after onset.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of HD rests on positive family history, characteristic clinical findings, and the detection of an expansion of 36 or more CAG trinucleotide repeats in <i>HTT</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Pharmacologic therapy including typical neuroleptics (haloperidol), atypical neuroleptics (olanzapine), benzodiazepines, or the monoamine depleting agent tetrabenazine for choreic movements; anti-parkinsonian agents for hypokinesia and rigidity; psychotropic drugs or some types of antiepileptic drugs for psychiatric disturbances (depression, psychotic symptoms, outbursts of aggression); valproic acid for myoclonic hyperkinesia. Supportive care with attention to nursing needs, dietary intake, special equipment, and eligibility for state and federal benefits.</p><p><i>Prevention of secondary complications:</i> Attention to the usual potential complications in persons requiring long-term supportive care and the side effects associated with pharmacologic treatments.</p><p><i>Surveillance:</i> Regular evaluations of the appearance and severity of chorea, rigidity, gait problems, depression, behavioral changes, and cognitive decline; routine assessment of functional abilities using the Behavior Observation Scale Huntington (BOSH) and the Unified HD rating scale (UHDRS).</p><p><i>Agents/circumstances to avoid:</i> L-dopa-containing compounds (may increase chorea), alcohol consumption, smoking.</p><p><i>Other:</i> Children and adolescents with a parent with HD may benefit from referral to a local HD support group for educational materials and psychological support.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>HD is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Offspring of an individual with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a 50% chance of inheriting the disease-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Predictive testing in asymptomatic adults at risk is available but requires careful thought (including pre- and post-test <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>) as there is currently no cure for the disorder. However, asymptomatic individuals at risk may be eligible to participate in clinical trials. Predictive testing is not considered appropriate for asymptomatic at-risk individuals younger than age 18 years. Prenatal testing by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is possible.</p></div></div><div id="huntington.Diagnosis"><h2 id="_huntington_Diagnosis_">Diagnosis</h2><div id="huntington.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Huntington disease (HD) <b>should be suspected</b> in individuals with any of the following:</p><ul><li class="half_rhythm"><div>Progressive motor disability featuring chorea. Voluntary movement may also be affected.</div></li><li class="half_rhythm"><div>Mental disturbances including cognitive decline, changes in personality, and/or depression</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance</div></li></ul><p>Note: The appearance and sequence of motor, cognitive, and psychiatric disturbances can be variable in HD (see <a href="#huntington.Clinical_Description">Clinical Description</a>).</p></div><div id="huntington.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of HD <b>is confirmed</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinical signs and symptoms of HD by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> expansion of a CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> in <i>HTT</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1305/table/huntington.T.molecular_genetic_testing_u/?report=objectonly" target="object" rid-figpopup="fighuntingtonTmoleculargenetictestingu" rid-ob="figobhuntingtonTmoleculargenetictestingu">Table 1</a>).</p><p><b>Allele sizes.</b> All individuals with HD have an expansion in the number of CAG trinucleotide repeats that encode glutamine amino acids in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 of <i>HTT</i>.</p><ul><li class="half_rhythm"><div><b>Normal alleles.</b> 26 or fewer CAG trinucleotide repeats.</div></li><li class="half_rhythm"><div><b>Intermediate alleles.</b> 27-35 CAG trinucleotide repeats. An individual with an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in this range is not at risk of developing symptoms of HD but, because of instability in the CAG tract, may be at risk of having a child with an allele in the HD-causing range [<a class="bk_pop" href="#huntington.REF.semaka.2006.283">Semaka et al 2006</a>]. Risk estimates for <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> CAG expansion have been established [<a class="bk_pop" href="#huntington.REF.semaka.2013b.696">Semaka et al 2013b</a>, <a class="bk_pop" href="#huntington.REF.semaka.2014.303">Semaka &#x00026; Hayden 2014</a>].</div></li><li class="half_rhythm"><div><b>HD-causing alleles.</b> 36 or more CAG trinucleotide repeats. Persons who have an HD-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> are considered at risk of developing HD in their lifetime. HD-causing alleles are further classified as:</div><ul><li class="half_rhythm"><div><b>Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> HD-causing alleles.</b> 36-39 CAG trinucleotide repeats. An individual with an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in this range is at risk for HD but may not develop symptoms. Elderly asymptomatic individuals with CAG repeats in this range are common [<a class="bk_pop" href="#huntington.REF.kay.2016.282">Kay et al 2016</a>].</div></li><li class="half_rhythm"><div><b>Full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> HD-causing alleles.</b> 40 or more CAG trinucleotide repeats. Alleles of this size are associated with development of HD with increased certainty assuming a normal life span.</div></li></ul></li></ul><p>Molecular genetic testing approaches include <b>targeted testing</b> for the CAG repeat size in <i>HTT</i>.</p><div id="huntington.T.molecular_genetic_testing_u" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Huntington Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1305/table/huntington.T.molecular_genetic_testing_u/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__huntington.T.molecular_genetic_testing_u_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_huntington.T.molecular_genetic_testing_u_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_huntington.T.molecular_genetic_testing_u_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_huntington.T.molecular_genetic_testing_u_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_huntington.T.molecular_genetic_testing_u_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HTT</i></td><td headers="hd_h_huntington.T.molecular_genetic_testing_u_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_huntington.T.molecular_genetic_testing_u_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>4</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="huntington.TF.1.1"><p class="no_margin">See <a href="/books/NBK1305/#huntington.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="huntington.TF.1.2"><p class="no_margin">See <a href="#huntington.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="huntington.TF.1.3"><p class="no_margin">Detects CAG <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> number. <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>-based methods detect alleles up to about 115 CAG repeats [<a class="bk_pop" href="#huntington.REF.potter.2004.61">Potter et al 2004</a>, <a class="bk_pop" href="#huntington.REF.levin.2006.587">Levin et al 2006</a>]. Other methods may occasionally be useful to identify large CAG repeat tracts associated with juvenile-onset HD or to confirm an apparent <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> obtained by conventional PCR analysis. Other methods may include triplet repeat-primed PCR [<a class="bk_pop" href="#huntington.REF.jama.2013.255">Jama et al 2013</a>] or <a class="def" href="/books/n/gene/glossary/def-item/southern-blot/">Southern blot</a> analysis [<a class="bk_pop" href="#huntington.REF.bean.2014.e2">Bean &#x00026; Bayrak-Toydemir 2014</a>]. See <a class="bk_pop" href="#huntington.REF.benjamin.1994.606">Benjamin et al [1994]</a> for further considerations for predictive testing related to HD.</p></div></dd><dt>4. </dt><dd><div id="huntington.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#huntington.REF.macdonald.1993.971">MacDonald et al [1993]</a></p></div></dd></dl></div></div></div><p>Note: For comprehensive recommendations pertaining to predictive genetic testing for HD, see Genetic Counseling, <a href="#huntington.Related_Genetic_Counseling_Is">Related Genetic Counseling Issues</a> and <a class="bk_pop" href="#huntington.REF.macleod.2013.221">MacLeod et al [2013]</a>.</p></div></div><div id="huntington.Clinical_Characteristics"><h2 id="_huntington_Clinical_Characteristics_">Clinical Characteristics</h2><div id="huntington.Clinical_Description"><h3>Clinical Description</h3><p>During the prodromal phase of Huntington disease (HD) individuals may have subtle changes in motor skills, cognition, and personality (<a class="figpopup" href="/books/NBK1305/figure/huntington.F1/?report=objectonly" target="object" rid-figpopup="fighuntingtonF1" rid-ob="figobhuntingtonF1">Figure 1</a>) [<a class="bk_pop" href="#huntington.REF.tabrizi.2013.637">Tabrizi et al 2013</a>, <a class="bk_pop" href="#huntington.REF.ross.2014.204">Ross et al 2014</a>, <a class="bk_pop" href="#huntington.REF.liu.2015.2691">Liu et al 2015</a>]. These subtle changes can occur as early as 15-20 years prior to the clinical onset of manifest HD.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighuntingtonF1" co-legend-rid="figlgndhuntingtonF1"><a href="/books/NBK1305/figure/huntington.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="fighuntingtonF1" rid-ob="figobhuntingtonF1"><img class="small-thumb" src="/books/NBK1305/bin/huntington-Image001.gif" src-large="/books/NBK1305/bin/huntington-Image001.jpg" alt="Figure 1. . Natural history of Huntington disease (HD)." /></a><div class="icnblk_cntnt" id="figlgndhuntingtonF1"><h4 id="huntington.F1"><a href="/books/NBK1305/figure/huntington.F1/?report=objectonly" target="object" rid-ob="figobhuntingtonF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Natural history of Huntington disease (HD). Presymptomatic individuals are free from signs and symptoms of HD. During the prodromal phase, subtle signs and symptoms may be present prior to the diagnosis of HD, which is usually based on motor symptoms. <a href="/books/NBK1305/figure/huntington.F1/?report=objectonly" target="object" rid-ob="figobhuntingtonF1">(more...)</a></p></div></div><p><a class="bk_pop" href="#huntington.REF.reilmann.2014.1335">Reilmann et al [2014]</a> present guidelines for the diagnostic criteria of presymptomatic, prodromal, and manifest HD; see <a class="figpopup" href="/books/NBK1305/table/huntington.T.categories_of_huntington_di/?report=objectonly" target="object" rid-figpopup="fighuntingtonTcategoriesofhuntingtondi" rid-ob="figobhuntingtonTcategoriesofhuntingtondi">Table 2</a>. This table can be used to place individuals into different diagnostic categories, which may have clinical management implications over time. For example, awareness of presymptomatic and prodromal HD may allow for preventive (rather than symptomatic) therapies. Note the clear differentiation of genetically confirmed HD in the classification system.</p><div id="huntington.T.categories_of_huntington_di" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Categories of Huntington Disease Diagnosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1305/table/huntington.T.categories_of_huntington_di/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__huntington.T.categories_of_huntington_di_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_huntington.T.categories_of_huntington_di_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:top;">HD Classification</th><th id="hd_h_huntington.T.categories_of_huntington_di_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_2" style="text-align:left;vertical-align:middle;">HD Signs/Symptoms</th></tr><tr><th headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_1" id="hd_h_huntington.T.categories_of_huntington_di_1_1_2_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Genetically Confirmed</th><th headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_1" id="hd_h_huntington.T.categories_of_huntington_di_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NOT Genetically Confirmed</th></tr></thead><tbody><tr><td headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_1 hd_h_huntington.T.categories_of_huntington_di_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Presymptomatic HD:</b> HD, genetically confirmed, presymptomatic</td><td headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_1 hd_h_huntington.T.categories_of_huntington_di_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Clinically at risk for HD:</b> HD, not genetically confirmed, clinically at risk</td><td headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>No clinical motor signs/symptoms (motor DCL = 0 or 1)</div></li><li class="half_rhythm"><div>No cognitive signs/symptoms</div></li><li class="half_rhythm"><div>May have changes in imaging, quantitative motor assessments, or other biomarkers</div></li><li class="half_rhythm"><div>No symptomatic treatment indicated</div></li><li class="half_rhythm"><div>Disease-modifying treatment when safe &#x00026; available</div></li></ul>
</td></tr><tr><td headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_1 hd_h_huntington.T.categories_of_huntington_di_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Prodromal HD:</b> HD, genetically confirmed, prodromal</td><td headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_1 hd_h_huntington.T.categories_of_huntington_di_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Clinically prodromal HD:</b> HD, not genetically confirmed, clinically prodromal</td><td headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Subtle motor signs (usually motor DCL = 2) AND/OR subtle cognitive signs or symptoms</div></li><li class="half_rhythm"><div>Minor decline from individual premorbid level of function possibly detectable, but not required &#x00026; not detectable on TFC</div></li><li class="half_rhythm"><div>Apathy or depression or other behavioral changes judged related to HD may be present</div></li><li class="half_rhythm"><div>Usually changes in imaging &#x00026; quantitative motor assessments</div></li><li class="half_rhythm"><div>May/may not require symptomatic treatment (e.g., for depression)</div></li><li class="half_rhythm"><div>Disease-modifying treatment appropriate</div></li></ul>
</td></tr><tr><td headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_1 hd_h_huntington.T.categories_of_huntington_di_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Manifest</b>
<b>HD:</b> HD, genetically confirmed, manifest</td><td headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_1 hd_h_huntington.T.categories_of_huntington_di_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Clinically manifest HD:</b> HD, not genetically confirmed, clinically manifest&#x000a0;<sup>1</sup></td><td headers="hd_h_huntington.T.categories_of_huntington_di_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Presence of clinical motor and/or cognitive signs &#x00026; symptoms that have an impact on life, with:</div><ul><li class="half_rhythm"><div>Functional changes (e.g., &#x02193;TFC);</div></li><li class="half_rhythm"><div>Motor DCL = 3 or 4 (or motor DCL of 2 if cognitive changes significant AND evidence of progression)</div></li></ul></li><li class="half_rhythm"><div>Symptomatic and disease-modifying treatment appropriate</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#huntington.REF.reilmann.2014.1335">Reilmann et al [2014]</a>; used with permission</p></div></dd><dt></dt><dd><div><p class="no_margin">DCL = diagnostic confidence level from the UHDRS rating scale; HD = Huntington disease; TFC = total functional capacity</p></div></dd><dt>1. </dt><dd><div id="huntington.TF.2.1"><p class="no_margin">Requires motor DCL = 4, plus cognitive changes</p></div></dd></dl></div></div></div><p>The mean age of onset for HD is approximately 45 years [<a class="bk_pop" href="#huntington.REF.bates.2015.15005">Bates et al 2015</a>]. About two thirds of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals first present with neurologic manifestations; others present with psychiatric changes. In the early stages following diagnosis, manifestations include subtle changes in eye movements, coordination, minor involuntary movements, difficulty in mental planning, and often a depressed or irritable mood (see <a class="figpopup" href="/books/NBK1305/table/huntington.T.onset_of_clinical_signs_and/?report=objectonly" target="object" rid-figpopup="fighuntingtonTonsetofclinicalsignsand" rid-ob="figobhuntingtonTonsetofclinicalsignsand">Table 3</a>). Affected individuals are usually able to perform most of their ordinary activities and to continue work [<a class="bk_pop" href="#huntington.REF.ross.2014.204">Ross et al 2014</a>, <a class="bk_pop" href="#huntington.REF.bates.2015.15005">Bates et al 2015</a>].</p><p>In approximately 25% of individuals with HD, the onset is delayed until after age 50 years, with some after age 70 years. These individuals have chorea, gait disturbances, and dysphagia, but a more prolonged and benign course than the typical individual.</p><p>In the next stage, chorea becomes more prominent, voluntary activity becomes increasingly difficult, and dysarthria and dysphagia worsen. Most individuals are forced to give up their employment and depend increasingly on others for help, although they are still able to maintain a considerable degree of personal independence. The impairment is usually considerable, sometimes with intermittent outbursts of aggressive behaviors and social disinhibition.</p><p>In late stages of HD, motor disability becomes severe and the individual is often totally dependent, mute, and incontinent. The median survival time after onset is 15 to 18 years (range: 5 to &#x0003e;25 years). The average age at death is 54 to 55 years [<a class="bk_pop" href="#huntington.REF.bates.2015.15005">Bates et al 2015</a>].</p><div id="huntington.T.onset_of_clinical_signs_and" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Onset of Clinical Signs and Symptoms in HD</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1305/table/huntington.T.onset_of_clinical_signs_and/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__huntington.T.onset_of_clinical_signs_and_lrgtbl__"><table><thead><tr><th id="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:top;">Clinical Signs in HD</th></tr></thead><tbody><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" rowspan="11" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Early</b></td><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clumsiness</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Agitation</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Irritability</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Apathy</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Anxiety</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Disinhibition</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Delusions</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Hallucinations</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Abnormal eye movements</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Depression</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Olfactory dysfunction</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" rowspan="12" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Middle</b></td><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystonia</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Involuntary movements</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Trouble w/balance &#x00026; walking</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Chorea, twisting &#x00026; writhing motions, jerks, staggering, swaying, disjointed gait (can seem like intoxication)</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Trouble w/activities that require manual dexterity</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Slow voluntary movements, difficulty initiating movement</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Inability to control speed &#x00026; force of movement</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Slow reaction time</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">General weakness</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Weight loss</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Speech difficulties</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Stubbornness</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" rowspan="8" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Late</b></td><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rigidity</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Bradykinesia (difficulty initiating &#x00026; continuing movements)</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Severe chorea (less common)</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Significant weight loss</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Inability to walk</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Inability to speak</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Swallowing problems, danger of choking</td></tr><tr><td headers="hd_h_huntington.T.onset_of_clinical_signs_and_1_1_1_1" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Inability to care for oneself</td></tr></tbody></table></div></div><p><b>Abnormalities of movement.</b> Disturbances of both involuntary and voluntary movements occur in individuals with HD. Chorea, an involuntary movement disorder consisting of non-repetitive, non-periodic jerking of limbs, face, or trunk, is the major sign of the disease. Chorea is present in more than 90% of individuals, and typically increases in severity during the first ten years. The choreic movements are continuously present during waking hours, cannot be suppressed voluntarily, and are worsened by stress.</p><p>With advancing disease duration, other involuntary movements such as bradykinesia, rigidity, and dystonia occur. Impairment in voluntary motor function is an early sign. Affected individuals and their families describe clumsiness in common daily activities. Motor speed, fine motor control, and gait are affected. Oculomotor disturbances occur early and worsen progressively. Difficulty in initiating ocular saccades, slow and hypometric saccades, and problems in gaze fixation may be seen in up to 75% of symptomatic individuals [<a class="bk_pop" href="#huntington.REF.blekher.2006.394">Blekher et al 2006</a>, <a class="bk_pop" href="#huntington.REF.golding.2006.485">Golding et al 2006</a>]. Dysarthria occurs early and is common. Dysphagia occurs in the late stages. Hyperreflexia occurs early in 90% of individuals, while clonus and extensor plantar responses occur late and less frequently.</p><p><b>Abnormalities of cognition.</b> A global and progressive decline in cognitive capabilities occurs in all individuals with HD. Cognitive changes include forgetfulness, slowness of thought processes, impaired visuospatial abilities, and impaired ability to manipulate acquired knowledge. Several studies have identified subtle but definite cognitive deficits prior to the onset of motor symptoms [<a class="bk_pop" href="#huntington.REF.bourne.2006.41">Bourne et al 2006</a>, <a class="bk_pop" href="#huntington.REF.montoya.2006.21">Montoya et al 2006</a>, <a class="bk_pop" href="#huntington.REF.paulsen.2008.874">Paulsen et al 2008</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2009.791">Tabrizi et al 2009</a>, <a class="bk_pop" href="#huntington.REF.rupp.2010.379">Rupp et al 2010</a>]. The initial changes often involve loss of mental flexibility and impairment of executive functions such as mental planning and organization of sequential activities.</p><p>Memory deficits with greater impairment for retrieval of information occur early, but verbal cues, priming, and sufficient time may lead to partial or correct recall. Early in the disease the memory deficits in HD are usually much less severe than in Alzheimer disease.</p><p>The overall cognitive and behavioral syndrome in individuals with HD is more similar to frontotemporal dementia than to Alzheimer disease. Attention and concentration are involved early [<a class="bk_pop" href="#huntington.REF.peinemann.2005.11">Peinemann et al 2005</a>], resulting in easy distractibility. Language functions are relatively preserved, but a diminished level of syntactic complexity, cortical speech abnormalities, paraphasic errors, and word-finding difficulties are common in late stages.</p><p>Neuropsychologic testing reveals impaired visuospatial abilities, particularly in late stages of the disease. Lack of awareness, especially of one's own disabilities, is common [<a class="bk_pop" href="#huntington.REF.ho.2006.385">Ho et al 2006</a>, <a class="bk_pop" href="#huntington.REF.bates.2015.15005">Bates et al 2015</a>].</p><p><b>Psychiatric disturbances.</b> Individuals with HD develop significant personality changes, affective psychosis, or schizophrenic psychosis [<a class="bk_pop" href="#huntington.REF.rosenblatt.2007.191">Rosenblatt 2007</a>]. Prior to onset of HD, they tend to score high on measures of depression, hostility, obsessive-compulsiveness, anxiety, and psychoticism [<a class="bk_pop" href="#huntington.REF.duff.2007.1341">Duff et al 2007</a>]. Unlike the progressive cognitive and motor disturbances, the psychiatric changes tend not to progress with disease severity [<a class="bk_pop" href="#huntington.REF.epping.2016.184">Epping et al 2016</a>]. Behavioral disturbances such as intermittent explosiveness, apathy, aggression, alcohol abuse, sexual dysfunction and deviations, and increased appetite are frequent. Delusions, often paranoid, are common. Hallucinations are less common.</p><p><b>Depression and suicide risk.</b> The incidence of depression in preclinical and symptomatic individuals is more than twice the general population [<a class="bk_pop" href="#huntington.REF.paulsen.2005b.496">Paulsen et al 2005b</a>, <a class="bk_pop" href="#huntington.REF.marshall.2007.116">Marshall et al 2007</a>]. The etiology of depression in HD is unclear; it may be a pathologic rather than a psychological consequence of having the disease [<a class="bk_pop" href="#huntington.REF.slaughter.2001.306">Slaughter et al 2001</a>, <a class="bk_pop" href="#huntington.REF.pouladi.2009.919">Pouladi et al 2009</a>]. Suicide and suicide ideation are common in persons with HD, but the incidence rate changes with disease course and predictive testing results [<a class="bk_pop" href="#huntington.REF.larsson.2006.361">Larsson et al 2006</a>, <a class="bk_pop" href="#huntington.REF.robins_wahlin.2007.279">Robins Wahlin 2007</a>, <a class="bk_pop" href="#huntington.REF.van_duijn.2018">van Duijn et al 2018</a>]. The critical periods for suicide risk were found to be just prior to receiving a diagnosis and later, when <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals experience a loss of independence [<a class="bk_pop" href="#huntington.REF.baliko.2004.258">Baliko et al 2004</a>, <a class="bk_pop" href="#huntington.REF.paulsen.2005a.725">Paulsen et al 2005a</a>, <a class="bk_pop" href="#huntington.REF.eddy.2016.1079">Eddy et al 2016</a>].</p><p><b>Other.</b> Persons with HD tend to have a lower body mass index than controls [<a class="bk_pop" href="#huntington.REF.pratley.2000.64">Pratley et al 2000</a>, <a class="bk_pop" href="#huntington.REF.stoy.2000.130">Stoy &#x00026; McKay 2000</a>, <a class="bk_pop" href="#huntington.REF.djouss_.2002.1325">Djouss&#x000e9; et al 2002</a>, <a class="bk_pop" href="#huntington.REF.robbins.2006.e7">Robbins et al 2006</a>], which may be related to altered metabolism [<a class="bk_pop" href="#huntington.REF.duan.2014.1366">Duan et al 2014</a>] and could represent a biomarker of clinical progression [<a class="bk_pop" href="#huntington.REF.van_der_burg.2017.479">van der Burg et al 2017</a>]. Individuals with HD also demonstrate disturbed cholesterol metabolism [<a class="bk_pop" href="#huntington.REF.valenza.2006.165">Valenza &#x00026; Cattaneo 2006</a>, <a class="bk_pop" href="#huntington.REF.wang.2014.231">Wang et al 2014</a>]. It is also common for persons with HD to demonstrate increased appetite and energy expenditure [<a class="bk_pop" href="#huntington.REF.pratley.2000.64">Pratley et al 2000</a>, <a class="bk_pop" href="#huntington.REF.trejo.2004.192">Trejo et al 2004</a>, <a class="bk_pop" href="#huntington.REF.gaba.2005.1335">Gaba et al 2005</a>].</p><p>Sleep and circadian rhythms are disrupted in individuals with HD [<a class="bk_pop" href="#huntington.REF.goodman.2010.882">Goodman &#x00026; Barker 2010</a>, <a class="bk_pop" href="#huntington.REF.morton.2013.34">Morton 2013</a>], possibly as a result of hypothalamic dysfunction [<a class="bk_pop" href="#huntington.REF.peters_n.2006.961">Peters&#x000e9;n &#x00026; Bj&#x000f6;rkqvist 2006</a>] and/or alterations in melatonin secretion [<a class="bk_pop" href="#huntington.REF.kalliolia.2014.1511">Kalliolia et al 2014</a>]. Insomnia and daytime somnolence may also be present, although this is more commonly due to psychiatric changes, depression, or chorea [<a class="bk_pop" href="#huntington.REF.videnovic.2009.471">Videnovic et al 2009</a>].</p><p><b>Neuropathology.</b> The primary neuropathologic feature of HD is degeneration of neurons in the caudate and putamen as well as the cerebral cortex [<a class="bk_pop" href="#huntington.REF.waldvogel.2015.33">Waldvogel et al 2015</a>]. The preferential degeneration of enkephalin-containing, medium spiny neurons of the indirect pathway of movement control in the basal ganglia provides the neurobiologic basis for chorea [<a class="bk_pop" href="#huntington.REF.galvan.2012.17">Galvan et al 2012</a>]. The additional loss of substance P-containing medium spiny neurons of the direct pathway results in akinesia and dystonia [<a class="bk_pop" href="#huntington.REF.galvan.2012.17">Galvan et al 2012</a>]. There is also evidence for loss of neurons in the globus pallidus, subthalamic nucleus, thalamus, hypothalamus, substantia nigra, and hippocampus [<a class="bk_pop" href="#huntington.REF.vonsattel.1985.559">Vonsattel et al 1985</a>, <a class="bk_pop" href="#huntington.REF.vonsattel.1998.369">Vonsattel &#x00026; DiFiglia 1998</a>, <a class="bk_pop" href="#huntington.REF.heinsen.1999.613">Heinsen et al 1999</a>, <a class="bk_pop" href="#huntington.REF.peters_n.2005.39">Peters&#x000e9;n et al 2005</a>, <a class="bk_pop" href="#huntington.REF.guo.2012.1379">Guo et al 2012</a>, <a class="bk_pop" href="#huntington.REF.dom_nguez.2013.e74131">Dom&#x000ed;nguez et al 2013</a>, <a class="bk_pop" href="#huntington.REF.singhbains.2016.185">Singh-Bains et al 2016</a>]. Region-specific patterns of neuronal loss in the basal ganglia and cortex may underlie the most evident symptoms in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and could contribute to the phenotypic variability among individuals [<a class="bk_pop" href="#huntington.REF.thu.2010.1094">Thu et al 2010</a>, <a class="bk_pop" href="#huntington.REF.hadzi.2012.1708">Hadzi et al 2012</a>, <a class="bk_pop" href="#huntington.REF.kim.2014.717">Kim et al 2014</a>, <a class="bk_pop" href="#huntington.REF.waldvogel.2015.33">Waldvogel et al 2015</a>, <a class="bk_pop" href="#huntington.REF.mehrabi.2016.67">Mehrabi et al 2016</a>]. Pathology is also observed in peripheral tissues [<a class="bk_pop" href="#huntington.REF.bj_rkqvist.2008.1869">Bj&#x000f6;rkqvist et al 2008</a>, <a class="bk_pop" href="#huntington.REF.van_der_burg.2009.765">van der Burg et al 2009</a>].</p><p>Intraneuronal inclusions containing huntingtin, the protein expressed from <i>HTT</i>, are also a prominent neuropathologic feature of the disease. However, the expression of the huntingtin protein and the pattern and timing of huntingtin-containing inclusions in the brain do not correlate with the selective degeneration of the disease and are not believed to be primary determinants of pathology [<a class="bk_pop" href="#huntington.REF.kuemmerle.1999.842">Kuemmerle et al 1999</a>, <a class="bk_pop" href="#huntington.REF.michalik.2003.r173">Michalik &#x00026; Van Broeckhoven 2003</a>, <a class="bk_pop" href="#huntington.REF.arrasate.2004.805">Arrasate et al 2004</a>, <a class="bk_pop" href="#huntington.REF.slow.2005.11402">Slow et al 2005</a>, <a class="bk_pop" href="#huntington.REF.slow.2006.408">Slow et al 2006</a>].</p><p><b>Neuroimaging.</b> Imaging studies provide additional support for the clinical diagnosis of HD and are valuable tools for studying progression of the disease [<a class="bk_pop" href="#huntington.REF.biglan.2009.1763">Biglan et al 2009</a>, <a class="bk_pop" href="#huntington.REF.paulsen.2009.272">Paulsen 2009</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2011.31">Tabrizi et al 2011</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2012.42">Tabrizi et al 2012</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2013.637">Tabrizi et al 2013</a>]. In addition to significant striatal atrophy in symptomatic individuals, regional and whole-brain gray and white matter changes have been detected [<a class="bk_pop" href="#huntington.REF.majid.2011.2544">Majid et al 2011</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2011.31">Tabrizi et al 2011</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2012.42">Tabrizi et al 2012</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2013.637">Tabrizi et al 2013</a>]. Furthermore, MRI studies have revealed progressive gray and white matter atrophy many years prior to predicted disease onset [<a class="bk_pop" href="#huntington.REF.tabrizi.2011.31">Tabrizi et al 2011</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2012.42">Tabrizi et al 2012</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2013.637">Tabrizi et al 2013</a>]. Numerous studies in recent years have used neuroimaging to elucidate the clinical progression of HD, with the specific interest of using these objective measures in clinical trials for testing efficacy of experimental therapeutics [<a class="bk_pop" href="#huntington.REF.tabrizi.2012.42">Tabrizi et al 2012</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2013.637">Tabrizi et al 2013</a>].</p><p><b>Juvenile HD</b> is defined by the onset of symptoms before age 20 years and accounts for 5%-10% of individuals with HD [<a class="bk_pop" href="#huntington.REF.gonzalezalegre.2006.223">Gonzalez-Alegre &#x00026; Afifi 2006</a>, <a class="bk_pop" href="#huntington.REF.quarrell.2013.3">Quarrell et al 2013</a>]. The motor, cognitive, and psychiatric disturbances observed in adult HD are also observed in juvenile HD, but the clinical presentation of these disturbances is different. Severe mental deterioration, prominent motor and cerebellar symptoms, speech and language delay, and rapid decline are also characteristic of juvenile HD [<a class="bk_pop" href="#huntington.REF.nance.2001.153">Nance &#x00026; Myers 2001</a>, <a class="bk_pop" href="#huntington.REF.gonzalezalegre.2006.223">Gonzalez-Alegre &#x00026; Afifi 2006</a>, <a class="bk_pop" href="#huntington.REF.squitieri.2006.208">Squitieri et al 2006</a>, <a class="bk_pop" href="#huntington.REF.yoon.2006.1265">Yoon et al 2006</a>]. Epileptic seizures, unique to the youngest-onset group, are present in 30%-50% of those with onset of HD before age ten years [<a class="bk_pop" href="#huntington.REF.gonzalezalegre.2006.223">Gonzalez-Alegre &#x00026; Afifi 2006</a>].</p><p>In teenagers, symptoms are more similar to adult HD, in which chorea and severe behavioral disturbances are common initial manifestations [<a class="bk_pop" href="#huntington.REF.nance.2001.153">Nance &#x00026; Myers 2001</a>].</p><p><b>Intermediate alleles (IA).</b> An individual with a CAG repeat in the 27-35 range is not believed to be at risk of developing HD but, because of instability in the CAG tract, may be at risk of having a child with an <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in the pathogenic CAG range [<a class="bk_pop" href="#huntington.REF.semaka.2006.283">Semaka et al 2006</a>, <a class="bk_pop" href="#huntington.REF.kay.2018.346">Kay et al 2018</a>]. Limited data suggest that individuals with IAs may exhibit behavioral changes as well as motor and cognitive impairments, although more research is required in this regard [<a class="bk_pop" href="#huntington.REF.killoran.2013.2022">Killoran et al 2013</a>, <a class="bk_pop" href="#huntington.REF.cubo.2016.571">Cubo et al 2016</a>].</p></div><div id="huntington.GenotypePhenotype_Correlation"><h3>Genotype-Phenotype Correlations</h3><p>A significant inverse correlation exists between the number of CAG repeats and the age of onset of HD [<a class="bk_pop" href="#huntington.REF.langbehn.2004.267">Langbehn et al 2004</a>, <a class="bk_pop" href="#huntington.REF.langbehn.2010.397">Langbehn et al 2010</a>]. See <a href="#huntington.Molecular_Genetics">Molecular Genetics</a>.</p><ul><li class="half_rhythm"><div>Individuals with adult onset of symptoms usually have an <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with CAG repeats ranging from 36 to 55.</div></li><li class="half_rhythm"><div>Individuals with juvenile onset of symptoms usually have an <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with CAG repeats greater than 60.</div></li><li class="half_rhythm"><div>Intermediate alleles (ranging from 27 to 35 CAG repeats) usually do not confer the disease <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> but are prone to CAG repeat instability [<a class="bk_pop" href="#huntington.REF.semaka.2013c.864">Semaka et al 2013c</a>].</div></li></ul><p>For data on the age-specific likelihood of onset by <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> size, see <a href="http://cmmt.ubc.ca/legacyfiles/pdf_hayden_supplementary_tables.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">cmmt.ubc.ca</a> (pdf).</p><p>In addition to age at clinical onset, CAG repeat length has also been shown to predict age at death, but not the duration of the illness [<a class="bk_pop" href="#huntington.REF.keum.2016.287">Keum et al 2016</a>].</p><p>The rate of deterioration of motor, cognitive, and functional measures increases with larger CAG repeat sizes [<a class="bk_pop" href="#huntington.REF.aziz.2009.1280">Aziz et al 2009</a>, <a class="bk_pop" href="#huntington.REF.chao.2017.79">Chao et al 2017</a>].</p><p>The progression of behavioral symptoms appears not to be related to repeat size [<a class="bk_pop" href="#huntington.REF.ravina.2008.1223">Ravina et al 2008</a>].</p><p>Homozygotes for fully penetrant HD alleles appear to have a similar age of onset to heterozygotes, but may exhibit an accelerated rate of disease progression [<a class="bk_pop" href="#huntington.REF.squitieri.2011.1599">Squitieri et al 2011</a>, <a class="bk_pop" href="#huntington.REF.lee.2012.690">Lee et al 2012</a>].</p><p>A significant negative correlation also exists between CAG size and <i>variability</i> of onset, in which more variability in the late age of onset is associated with smaller CAG sizes, suggesting that non-CAG modifiers may have a greater effect at lower CAG sizes than at larger CAG sizes [<a class="bk_pop" href="#huntington.REF.langbehn.2004.267">Langbehn et al 2004</a>, <a class="bk_pop" href="#huntington.REF.gusella.2009.80">Gusella &#x00026; Macdonald 2009</a>]. On average, the CAG repeat size accounts for up to 70% of the variability in age of onset, with an estimated 10%-20% of the residual variability being accounted for by heritable factors [<a class="bk_pop" href="#huntington.REF.li.2006.71">Li et al 2006</a>, <a class="bk_pop" href="#huntington.REF.gusella.2009.80">Gusella &#x00026; Macdonald 2009</a>]. Many genes at other loci have been shown to account for small amounts of this heritable portion of the variability [<a class="bk_pop" href="#huntington.REF.lee.2015.516">Lee et al 2015</a>].</p><p>Significant progress has been made in recent years in the identification of these additional <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> modifiers, both at the <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and throughout the genome. A variant in an NF-kB <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> binding site in the <i>HTT</i> promoter has been associated with both reduced expression of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and changes in the age of onset of HD [<a class="bk_pop" href="#huntington.REF.be_anovi_.2015.807">Be&#x0010d;anovi&#x00107; et al 2015</a>]. When this promoter variant is present on the normal <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, it is associated with an earlier age of onset of HD, while an opposite effect is observed when the promoter variant is present on the HD-causing allele. Further, genome-wide association studies have begun to shed light on other candidate modifier genes for HD [<a class="bk_pop" href="#huntington.REF.lee.2015.516">Lee et al 2015</a>, <a class="bk_pop" href="#huntington.REF.moss.2017.701">Moss et al 2017</a>]. These analyses have shown the important role of biologic pathways involved in DNA repair, mitochondrial fission, and oxidoreductase activity with regard to this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, and have identified candidate modifier genes for future study (e.g., <i>FAN1</i>, <i>MLH1</i>, <i>MTMR10</i>, <i>MSH3</i>, and <i>RRM2B</i>).</p></div><div id="huntington.Penetrance"><h3>Penetrance</h3><p>Alleles that contain 36 or more CAG repeats are considered HD-causing alleles and confer risk of developing the disease.</p><p>Alleles that contain from 36 to 39 CAG repeats, however, are incompletely penetrant and may or may not result in HD. Elderly asymptomatic individuals with CAG repeats in this range are common [<a class="bk_pop" href="#huntington.REF.kay.2016.282">Kay et al 2016</a>].</p><p>Alleles that contain more than 40 CAG repeats are completely penetrant. No asymptomatic elderly individuals with alleles of more than 40 CAG repeats have been reported.</p></div><div id="huntington.Anticipation"><h3>Anticipation</h3><p>Anticipation, the phenomenon in which increasing disease severity or decreasing age of onset is observed in successive generations, is known to occur in HD. Anticipation occurs far more commonly in paternal transmission of the mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. The phenomenon of <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> arises from instability of the CAG repeat during spermatogenesis [<a class="bk_pop" href="#huntington.REF.semaka.2013b.696">Semaka et al 2013b</a>]. Large expansions (i.e., an increase in allele size of &#x0003e;7 CAG repeats) occur almost exclusively through paternal transmission. Most often children with juvenile-onset disease inherit the expanded allele from their fathers, although on occasion they inherit it from their mothers [<a class="bk_pop" href="#huntington.REF.nahhas.2005.328">Nahhas et al 2005</a>].</p></div><div id="huntington.Nomenclature"><h3>Nomenclature</h3><p>In the pre-molecular-genetic era, there were many different names for chorea, including St. Vitus's Dance and Sydenham's chorea.</p><p>Juvenile HD, or childhood-onset HD, was previously called the Westphal variant of HD.</p><p>Individuals who do not yet show symptoms are in the premanifest phase of HD. Individuals who have been diagnosed with chorea and/or other validated signs of the disorder have manifest HD.</p></div><div id="huntington.Prevalence"><h3>Prevalence</h3><p>HD prevalence varies dramatically across world regions. Populations of European ancestry display an average prevalence of 9.71 per 100,000 [<a class="bk_pop" href="#huntington.REF.rawlins.2016.144">Rawlins et al 2016</a>], but estimates as high as 17 per 100,000 have been reported [<a class="bk_pop" href="#huntington.REF.fisher.2014.105">Fisher &#x00026; Hayden 2014</a>, <a class="bk_pop" href="#huntington.REF.baig.2016.1396">Baig et al 2016</a>]. In contrast, HD appears much less frequently in Japan, China, Korea, and Finland, as well as in indigenous African populations from South Africa, with estimated prevalence values ranging from 0.1 to 2 per 100,000 [<a class="bk_pop" href="#huntington.REF.pringsheim.2012.1083">Pringsheim et al 2012</a>, <a class="bk_pop" href="#huntington.REF.sipil_.2015.46">Sipil&#x000e4; et al 2015</a>, <a class="bk_pop" href="#huntington.REF.xu.2015.1815">Xu &#x00026; Wu 2015</a>].</p><p>Individuals living in the Lake Maracaibo region of Venezuela are believed to have the highest prevalence of HD in the world [<a class="bk_pop" href="#huntington.REF.wexler.2004.3498">Wexler et al 2004</a>].</p><p>The uneven distribution of HD is at least partially explained by the distribution of specific predisposing alleles and haplotypes in the general population of these ethnic groups [<a class="bk_pop" href="#huntington.REF.warby.2009.351">Warby et al 2009</a>, <a class="bk_pop" href="#huntington.REF.warby.2011.561">Warby et al 2011</a>, <a class="bk_pop" href="#huntington.REF.kay.2018.346">Kay et al 2018</a>]. For example, a recent study of 15 diverse global populations demonstrated that the mean CAG size in a population as well as intermediate <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> correlates with HD prevalence and contributes to differences in disease prevalence across major ancestry groups [<a class="bk_pop" href="#huntington.REF.kay.2018.346">Kay et al 2018</a>].</p><p>Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> <i>HTT</i> alleles (see <a href="#huntington.Establishing_the_Diagnosis">Establishing the Diagnosis</a>, <b>Allele sizes</b>) have recently been shown to occur at a high frequency in the general population, with as many as one in 400 individuals carrying these alleles &#x02013; although the penetrance rate was determined to be lower than previously reported (i.e., 0.2-2% for 36-38 CAG alleles) [<a class="bk_pop" href="#huntington.REF.kay.2016.282">Kay et al 2016</a>].</p></div></div><div id="huntington.Genetically_Related_Allelic_D"><h2 id="_huntington_Genetically_Related_Allelic_D_">Genetically Related (Allelic) Disorders</h2><p>Biallelic pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>HTT</i> are reported to cause the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> neurodevelopmental disorder Lopes-Maciel-Rodan Syndrome (LOMARS; OMIM <a href="https://omim.org/entry/617435" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617435</a>). Individuals with LOMARS present in childhood with a Rett syndrome-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and intellectual disability.</p></div><div id="huntington.Differential_Diagnosis"><h2 id="_huntington_Differential_Diagnosis_">Differential Diagnosis</h2><p>Huntington disease (HD) falls into the differential diagnosis of chorea, dementia, and psychiatric disturbances. The differential diagnosis of several HD-like disorders is summarized here and reviewed elsewhere [<a class="bk_pop" href="#huntington.REF.schneider.2007.517">Schneider et al 2007</a>, <a class="bk_pop" href="#huntington.REF.martino.2013.650">Martino et al 2013</a>]. The co-occurrence of Alzheimer disease and HD has also been reported [<a class="bk_pop" href="#huntington.REF.davis.2014.209">Davis et al 2014</a>].</p><p><b>Noninherited conditions</b> are associated with chorea, but most can be excluded easily in an individual with suspected HD based on associated findings and the course of illness. Causes of chorea include tardive dyskinesia, levodopa-induced dyskinesia, thyrotoxicosis, cerebrovascular disease, cerebral lupus, polycythemia, and group A beta-hemolytic <i>Streptococcus</i>.</p><p><b>Inherited conditions.</b> See <a class="figpopup" href="/books/NBK1305/table/huntington.T.inherited_conditions_to_con/?report=objectonly" target="object" rid-figpopup="fighuntingtonTinheritedconditionstocon" rid-ob="figobhuntingtonTinheritedconditionstocon">Table 4</a>.</p><div id="huntington.T.inherited_conditions_to_con" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Inherited Conditions to Consider in the Differential Diagnosis of Huntington Disease</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1305/table/huntington.T.inherited_conditions_to_con/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__huntington.T.inherited_conditions_to_con_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of the Disorder</th></tr><tr><th headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4" id="hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/HD</th><th headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4" id="hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from HD</th></tr></thead><tbody><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/als-ftd/">Frontotemporal dementia &#x00026;/or amyotrophic lateral sclerosis</a></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>C9orf72</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Movement disorders</div></li><li class="half_rhythm"><div>Dementia</div></li><li class="half_rhythm"><div>Psychiatric disturbances</div></li></ul>
</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Myoclonus</div></li><li class="half_rhythm"><div>Tremor</div></li><li class="half_rhythm"><div>Torticollis</div></li></ul>
</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Huntington disease-like 1<br />(HDL1; OMIM <a href="http://www.omim.org/entry/603218" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">603218</a>)&#x000a0;<sup>1</sup></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRNP</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Range of clinical features that overlap w/HD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Early onset</div></li><li class="half_rhythm"><div>Slow progression</div></li></ul>
</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hd-l2/">Huntington disease-like 2</a><br />(HDL2)</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>JPH3</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinically indistinguishable from HD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prevalence highest among &#x00026; perhaps exclusive to individuals of African descent</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/chac/">Chorea-acanthocytosis</a><br />(ChAc)</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>VPS13A</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Progressive movement disorder</div></li><li class="half_rhythm"><div>Progressive cognitive &#x00026; behavior changes</div></li></ul>
</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Myopathy</div></li><li class="half_rhythm"><div>Increased serum CK</div></li><li class="half_rhythm"><div>Acanthocytosis</div></li><li class="half_rhythm"><div>Seizures common</div></li><li class="half_rhythm"><div>Mean age of onset ~30 years</div></li></ul>
</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/mcleod/">McLeod neuroacanthocytosis syndrome</a> (MLS)</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XK</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Cognitive impairment</div></li><li class="half_rhythm"><div>Psychiatric symptoms</div></li></ul>
</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Acanthocytosis</div></li><li class="half_rhythm"><div>Compensated hemolysis</div></li><li class="half_rhythm"><div>McLeod blood group <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></div></li></ul>
</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sca17/">Spinocerebellar ataxia type 17</a> (SCA17)</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TBP</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Chorea</div></li><li class="half_rhythm"><div>Dementia</div></li><li class="half_rhythm"><div>Psychiatric disturbances</div></li></ul>
</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cerebellar ataxia is the prominent movement disorder.</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/drpla/">Dentatorubral-pallidoluysian atrophy</a> (DRPLA)</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATN1</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Progressive movement disorders &#x00026; dementia</div></li><li class="half_rhythm"><div>Psychiatric disturbances</div></li></ul>
</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ataxia &#x00026; myoclonus are prominent movement disorders.</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Benign hereditary chorea<br />(OMIM <a href="http://www.omim.org/entry/118700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">118700</a>)</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NKX2-1</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chorea</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Non-progressive chorea</div></li><li class="half_rhythm"><div>Not associated w/dementia</div></li></ul>
</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hereditary cerebellar ataxia (see <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>)</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR<br />XL</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Movement disorder</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hereditary cerebellar ataxia associated w/prominent cerebellar &#x00026; long tract signs</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Familial Creutzfeld-Jakob disease<br />(fCJD, see <a href="/books/n/gene/prion/">Genetic Prion Diseases</a>)</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRNP</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Typically late onset</div></li><li class="half_rhythm"><div>Progressive dementia</div></li><li class="half_rhythm"><div>Movement disorders</div></li><li class="half_rhythm"><div>Behavior changes</div></li><li class="half_rhythm"><div>Psychiatric symptoms</div></li></ul>
</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>fCJD progresses more rapidly.</div></li><li class="half_rhythm"><div>Myoclonus is a prominent involuntary movement.</div></li></ul>
</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/alzheimer/">Early-onset familial Alzheimer disease</a></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>APP</i><br /><i>PSEN1</i><br /><i>PSEN2</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dementia</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No movement disorders</td></tr><tr><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Familial frontotemporal dementia with parkinsonism-17</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MAPT</i></td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Late onset</div></li><li class="half_rhythm"><div>Progressive movement disorders, dementia, &#x00026; behavior changes</div></li><li class="half_rhythm"><div>Psychiatric disturbances</div></li></ul>
</td><td headers="hd_h_huntington.T.inherited_conditions_to_con_1_1_1_4 hd_h_huntington.T.inherited_conditions_to_con_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No chorea</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; CNS = central nervous system; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="huntington.TF.4.1"><p class="no_margin">HDL1 is caused by a specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (8 extra octapeptide repeats) in the prion protein <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, <i>PRNP</i>, on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 20p [<a class="bk_pop" href="#huntington.REF.laplanche.1999.2375">Laplanche et al 1999</a>, <a class="bk_pop" href="#huntington.REF.moore.2001.1385">Moore et al 2001</a>]. Similar pathogenic variants at this <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> also result in other forms of prion disease such as <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> Creutzfeldt-Jakob disease (see <a href="/books/n/gene/prion/">Genetic Prion Diseases</a>).</p></div></dd></dl></div></div></div><p>The diagnosis of HD in children is straightforward in a family with a history of HD. In <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with no known family history of HD), <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a>, <a href="/books/n/gene/pkan/">pantothenate kinase-associated neurodegeneration</a> (previously known as Hallervorden-Spatz syndrome), <a href="/books/n/gene/lns/">Lesch-Nyhan syndrome</a>, <a href="/books/n/gene/wilson/">Wilson disease</a>, progressive myoclonic epilepsy [<a class="bk_pop" href="#huntington.REF.gambardella.2001.708">Gambardella et al 2001</a>], and other metabolic diseases must be excluded.</p></div><div id="huntington.Management"><h2 id="_huntington_Management_">Management</h2><div id="huntington.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Huntington disease (HD), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Physical examination</div></li><li class="half_rhythm"><div>Neurologic assessment</div></li><li class="half_rhythm"><div>Assessment of the full range of motor, cognitive, and psychiatric symptoms associated with HD. Among a range of clinical scoring systems that have been described, the Unified Huntington's Disease Rating Scale (HDRS) provides a reliable and consistent assessment of the clinical features and progression of HD.</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="huntington.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Pharmacologic therapy is limited to symptomatic treatment [<a class="bk_pop" href="#huntington.REF.mestre.2009.cd006456">Mestre et al 2009</a>, <a class="bk_pop" href="#huntington.REF.killoran.2014.1404">Killoran &#x00026; Biglan 2014</a>].</p><ul><li class="half_rhythm"><div>Choreic movements can be partially suppressed by typical (haloperidol) and atypical (olanzapine) neuroleptics; benzodiazepines; or the monoamine-depleting agent tetrabenazine [<a class="bk_pop" href="#huntington.REF.de_tommaso.2005.280">de Tommaso et al 2005</a>, <a class="bk_pop" href="#huntington.REF.bonelli.2006.2701">Bonelli &#x00026; Wenning 2006</a>, <a class="bk_pop" href="#huntington.REF.huntington_study_group.2006.366">Huntington Study Group 2006</a>]. Tetrabenazine can be effective as an antichoreic drug; however, its use is associated with severe adverse effects such as extrapyramidal symptoms. Deutetrabenazine, a deuterated analog of tetrabenazine, has been modified by deuterium atom substitutions at specific sites on the molecule to increase half-life and systemic exposure [<a class="bk_pop" href="#huntington.REF.stamler.2013.210">Stamler et al 2013</a>]. These properties allow for less frequent dosing with fewer adverse effects [<a class="bk_pop" href="#huntington.REF.huntington_study_group.2016.40">Huntington Study Group 2016</a>, <a class="bk_pop" href="#huntington.REF.reilmann.2016.1404">Reilmann 2016</a>].</div></li><li class="half_rhythm"><div>Anti-parkinsonian agents may ameliorate hypokinesia and rigidity, but may increase chorea.</div></li><li class="half_rhythm"><div>Psychiatric disturbances such as depression, psychotic symptoms, and outbursts of aggression generally respond well to psychotropic drugs or some types of antiepileptic drugs.</div></li><li class="half_rhythm"><div>Valproic acid has improved myoclonic hyperkinesia in Huntington disease [<a class="bk_pop" href="#huntington.REF.saft.2006.11">Saft et al 2006</a>].</div></li></ul><p>Supportive care with attention to nursing, diet, special equipment, and eligibility for state and federal benefits is much appreciated by individuals with HD and their families. Numerous social problems beset individuals with HD and their families; practical help, emotional support, and counseling can provide relief [<a class="bk_pop" href="#huntington.REF.williams.2009.789">Williams et al 2009</a>].</p></div><div id="huntington.Prevention_of_Secondary_Compl"><h3>Prevention of Secondary Complications</h3><p>Significant secondary complications of HD include the following:</p><ul><li class="half_rhythm"><div>The complications typically observed with any individual requiring long-term supportive care</div></li><li class="half_rhythm"><div>The side effects associated with various pharmacologic treatments. Drug side effects are dependent on a variety of factors including the compound involved, the dosage, and the individual; but with the medications typically used in HD, side effects may include depression, sedation, nausea, restlessness, headache, neutropenia, and tardive dyskinesia. For some individuals, the side effects of certain therapeutics may be worse than the symptoms; such individuals would benefit from being removed from the treatment, having the dose reduced, or being "rested" regularly from the treatment. Current medications used to treat chorea are particularly prone to significant side effects. Individuals with mild to moderate chorea may be better assisted with non-pharmacologic therapies such as movement training and speech therapy.</div></li><li class="half_rhythm"><div>Depression. Standard treatment is appropriate when indicated [<a class="bk_pop" href="#huntington.REF.paulsen.2005b.496">Paulsen et al 2005b</a>, <a class="bk_pop" href="#huntington.REF.phillips.2008.1491">Phillips et al 2008</a>].</div></li></ul></div><div id="huntington.Surveillance"><h3>Surveillance</h3><p>Regular evaluations should be made to address the appearance and severity of chorea, rigidity, gait problems, depression, behavioral changes, and cognitive decline [<a class="bk_pop" href="#huntington.REF.anderson.2005.197">Anderson &#x00026; Marshall 2005</a>, <a class="bk_pop" href="#huntington.REF.skirton.2005.167">Skirton 2005</a>].</p><p>The Behavior Observation Scale Huntington (BOSH) is a scale developed for the rapid and longitudinal assessment of functional abilities of persons with HD in a nursing home environment [<a class="bk_pop" href="#huntington.REF.timman.2005.215">Timman et al 2005</a>]. For longitudinal studies, the Unified HD Rating Scale is used (UHDRS) [<a class="bk_pop" href="#huntington.REF.huntington_study_group.1996.136">Huntington Study Group 1996</a>, <a class="bk_pop" href="#huntington.REF.siesling.1998.915">Siesling et al 1998</a>, <a class="bk_pop" href="#huntington.REF.youssov.2013.1717">Youssov et al 2013</a>]. The total functional capacity (TFC) scale is used to describe the progression of HD, the level of functioning, and requirements for additional caregiver aid (<a href="http://promotingexcellence.growthhouse.org/huntingtons/monograph/pe5670.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TFC scale</a>).</p></div><div id="huntington.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>L-dopa-containing compounds may increase chorea.</p><p>Alcohol and smoking are discouraged.</p></div><div id="huntington.Evaluation_of_Relatives_at_Ri"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#huntington.Related_Genetic_Counseling_Is">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="huntington.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A wide range of potential therapeutics are under investigation in both animal models of HD and human clinical trials [<a class="bk_pop" href="#huntington.REF.wild.2014.1434">Wild &#x00026; Tabrizi 2014</a>]. This diversity reflects the variety of cellular pathways known to be perturbed in HD [<a class="bk_pop" href="#huntington.REF.bonelli.2004.51">Bonelli et al 2004</a>, <a class="bk_pop" href="#huntington.REF.rego.2005.361">Rego &#x00026; de Almeida 2005</a>, <a class="bk_pop" href="#huntington.REF.borrellpag_s.2006.2642">Borrell-Pag&#x000e8;s et al 2006</a>, <a class="bk_pop" href="#huntington.REF.graham.2006.444">Graham et al 2006</a>, <a class="bk_pop" href="#huntington.REF.bonelli.2007.141">Bonelli &#x00026; Hofmann 2007</a>].</p><ul><li class="half_rhythm"><div>Pharmacologic agents being investigated include inhibitors of: apoptosis, excitotoxicity, huntingtin aggregation, huntingtin proteolysis, huntingtin phosphorylation, inflammation, oxidative damage, phosphodiesterase activity, histone deacetylase, and transglutaminase activity; as well as compounds that modulate mitochondrial function, chaperone activity, transcription, and neurotrophic support.</div></li><li class="half_rhythm"><div>Therapeutics that have shown improvements in preclinical animal models of HD and have been advanced to clinical trials include minocycline, sodium butyrate, essential fatty acids, racemide, creatine, cystamine, riluzole, memantine, resveratrol, cannabis extract (THC and CBD), coenzyme Q<sub>10</sub>, and a phosphodiesterase 10a inhibitor [<a class="bk_pop" href="#huntington.REF.bender.2005.36">Bender et al 2005</a>, <a class="bk_pop" href="#huntington.REF.puri.2005.286">Puri et al 2005</a>, <a class="bk_pop" href="#huntington.REF.bonelli.2006.2701">Bonelli &#x00026; Wenning 2006</a>, <a class="bk_pop" href="#huntington.REF.ondo.2007.453">Ondo et al 2007</a>, <a class="bk_pop" href="#huntington.REF.okamoto.2009.1407">Okamoto et al 2009</a>, <a class="bk_pop" href="#huntington.REF.huntington_study_group_domino_investigators.2010.2219">Huntington Study Group DOMINO Investigators 2010</a>, <a class="bk_pop" href="#huntington.REF.hersch.2017.594">Hersch et al 2017</a>, <a class="bk_pop" href="#huntington.REF.mcgarry.2017.152">McGarry et al 2017</a>]. Notably, many of these therapeutic agents have failed to meet clinical endpoints and demonstrate efficacy in modifying clinical progression of HD. Experimental therapeutics including pridopidine, laquinimod, and a semaphorin-4D neutralizing antibody are still in clinical development.</div></li><li class="half_rhythm"><div>Gene-silencing approaches to target the cause of HD have been shown to be safe and efficacious in preclinical animal studies and are currently undergoing or on the verge of entering clinical trials. These include approaches using RNA interference (RNAi) or antisense oligonucleotides (ASOs) [<a class="bk_pop" href="#huntington.REF.boudreau.2009.1053">Boudreau et al 2009</a>, <a class="bk_pop" href="#huntington.REF.pfister.2009.226">Pfister &#x00026; Zamore 2009</a>, <a class="bk_pop" href="#huntington.REF.hu.2010.1183">Hu et al 2010</a>, <a class="bk_pop" href="#huntington.REF.mcbride.2011.2152">McBride et al 2011</a>, <a class="bk_pop" href="#huntington.REF.kordasiewicz.2012.1031">Kordasiewicz et al 2012</a>, <a class="bk_pop" href="#huntington.REF.aronin.2014.1455">Aronin &#x00026; DiFiglia 2014</a>, <a class="bk_pop" href="#huntington.REF.dufour.2014.797">Dufour et al 2014</a>, <a class="bk_pop" href="#huntington.REF.stanek.2014.461">Stanek et al 2014</a>, <a class="bk_pop" href="#huntington.REF.pfister.2018.663">Pfister et al 2018</a>]. These approaches aim to either silence all huntingtin expression in a nonselective manner [<a class="bk_pop" href="#huntington.REF.boudreau.2009.1053">Boudreau et al 2009</a>, <a class="bk_pop" href="#huntington.REF.mcbride.2011.2152">McBride et al 2011</a>, <a class="bk_pop" href="#huntington.REF.kordasiewicz.2012.1031">Kordasiewicz et al 2012</a>] or are <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>-selective for only the mutated <i>HTT</i> allele [<a class="bk_pop" href="#huntington.REF.gagnon.2010.10166">Gagnon et al 2010</a>, <a class="bk_pop" href="#huntington.REF.carroll.2011.2178">Carroll et al 2011</a>, <a class="bk_pop" href="#huntington.REF.evers.2011.e24308">Evers et al 2011</a>, <a class="bk_pop" href="#huntington.REF.skotte.2014.e107434">Skotte et al 2014</a>, <a class="bk_pop" href="#huntington.REF.southwell.2014.2093">Southwell et al 2014</a>, <a class="bk_pop" href="#huntington.REF.datson.2017.e0171127">Datson et al 2017</a>]. Allele selectivity can be achieved by targeting the expanded CAG tract [<a class="bk_pop" href="#huntington.REF.gagnon.2010.10166">Gagnon et al 2010</a>, <a class="bk_pop" href="#huntington.REF.evers.2011.e24308">Evers et al 2011</a>, <a class="bk_pop" href="#huntington.REF.datson.2017.e0171127">Datson et al 2017</a>] or by targeting polymorphisms in linkage disequilibrium with the CAG expansion [<a class="bk_pop" href="#huntington.REF.carroll.2011.2178">Carroll et al 2011</a>, <a class="bk_pop" href="#huntington.REF.skotte.2014.e107434">Skotte et al 2014</a>, <a class="bk_pop" href="#huntington.REF.southwell.2014.2093">Southwell et al 2014</a>, <a class="bk_pop" href="#huntington.REF.kay.2015.1759">Kay et al 2015</a>]. Top-line data from the first in-human Phase I/IIa clinical trial evaluating the <i>HTT</i> targeted ASO showed that IONIS-HTT<sub>Rx</sub> (RG6042) was well tolerated at all doses tested and resulted in dose-dependent reductions of mHTT in the cerebrospinal fluid (CSF) (<a href="http://ir.ionispharma.com/node/23401/pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">IONIS&#x02122; press release 3-1-18</a>).</div></li><li class="half_rhythm"><div>Cell transplantation studies in HD have shown variable results with small numbers of individuals [<a class="bk_pop" href="#huntington.REF.furtado.2005.331">Furtado et al 2005</a>, <a class="bk_pop" href="#huntington.REF.bachoudl_vi.2006.303">Bachoud-L&#x000e9;vi et al 2006</a>, <a class="bk_pop" href="#huntington.REF.farrington.2006.279">Farrington et al 2006</a>, <a class="bk_pop" href="#huntington.REF.dunnett.2007.279">Dunnett &#x00026; Rosser 2007</a>, <a class="bk_pop" href="#huntington.REF.barker.2013.657">Barker et al 2013</a>]; however, additional larger studies are under way [<a class="bk_pop" href="#huntington.REF.lopez.2014.259">Lopez et al 2014</a>]. Moreover, the safety and efficacy of intravenously injected mesenchymal stem cells is currently being tested in a first-in-human clinical trial for individuals with HD (NCT02728115). Of concern, recent studies suggest that mutated huntingtin is capable of spreading into the allografted neural tissue [<a class="bk_pop" href="#huntington.REF.cicchetti.2014.31">Cicchetti et al 2014</a>].</div></li></ul><p>Numerous human clinical trials are planned or under way for HD and are listed at <a href="http://www.huntington-study-group.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntington-study-group.org</a>. A number of drug trials have been completed and/or are ongoing. For example, both a high-dose creatine trial and trials using SD-809 (a modified form of tetrabenazine [Xenazine<sup>&#x000ae;</sup>, Nitoman<sup>&#x000ae;</sup>]) are in Phase III clinical testing. A Phase II clinical trial is also under way for PBT2. For the most up-to-date information see <a href="http://hddrugworks.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">hddrugworks.org</a>.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div><div id="huntington.Other"><h3>Other</h3><p><b>Biomarker studies,</b> such as TRACK-HD, PREDICT-HD, and ENROLL-HD, have been conducted to identify early changes in disease progression using imaging, clinical scales, and physiologic measurements [<a class="bk_pop" href="#huntington.REF.scahill.2012.371">Scahill et al 2012</a>, <a class="bk_pop" href="#huntington.REF.ross.2014.204">Ross et al 2014</a>]. Longitudinal studies of persons at risk for HD have also been performed [<a class="bk_pop" href="#huntington.REF.huntington_study_group_pharos_investigators.2006.991">Huntington Study Group PHAROS Investigators 2006</a>, <a class="bk_pop" href="#huntington.REF.paulsen.2006.883">Paulsen et al 2006</a>, <a class="bk_pop" href="#huntington.REF.tabrizi.2012.42">Tabrizi et al 2012</a>].</p><p>A number of candidate molecular biomarkers of disease onset and clinical progression have been assessed in HD patient cohorts, yet only a few have been validated. Mutated huntingtin levels in CSF have been shown to correlate with disease stage in HD [<a class="bk_pop" href="#huntington.REF.southwell.2015.12166">Southwell et al 2015</a>, <a class="bk_pop" href="#huntington.REF.wild.2015.1979">Wild et al 2015</a>] and potentially reflect levels of mHTT in the brain [<a class="bk_pop" href="#huntington.REF.southwell.2015.12166">Southwell et al 2015</a>]. Therefore, mHTT levels in CSF may provide a reliable biomarker of clinical progression and may provide a proxy measurement for HTT suppression in the brain for <i>HTT-</i>targeted clinical trials. Moreover, levels of neurofilament light chain in blood and CSF have been shown to be a potential prognostic biomarker of disease onset and clinical progression as well as regional brain atrophy in individuals with HD [<a class="bk_pop" href="#huntington.REF.byrne.2017.601">Byrne et al 2017</a>, <a class="bk_pop" href="#huntington.REF.johnson.2018.e717">Johnson et al 2018</a>].</p><p><b>Children and adolescents living with a parent <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with HD,</b> sometimes in very deprived conditions, can have special problems. Referral to a local HD support group for educational material and needed psychological support is helpful (see <a href="#huntington.Resources">Resources</a>).</p><p><b>Donepezil</b>, a drug used to treat Alzheimer disease, has not improved motor or cognitive function in HD [<a class="bk_pop" href="#huntington.REF.cubo.2006.1268">Cubo et al 2006</a>].</p></div></div><div id="huntington.Genetic_Counseling"><h2 id="_huntington_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="huntington.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Huntington disease (HD) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="huntington.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with HD have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with HD may appear to be negative for one of the following reasons:</div><ul><li class="half_rhythm"><div>Failure to recognize the disorder in family members</div></li><li class="half_rhythm"><div>Early death of the parent before the onset of symptoms</div></li><li class="half_rhythm"><div>The presence of an intermediate <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (see <b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b>) (range: 27-35 CAG repeats) or an <i>HTT</i> allele with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> (range: 36-39 CAG repeats) in an asymptomatic parent</div></li><li class="half_rhythm"><div>Late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent</div></li></ul></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who appears to represent a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family).</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of a proband depends on the genetic status of the proband's parent:</p><ul><li class="half_rhythm"><div class="half_rhythm">If a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has an <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with CAG length of 40 or greater, the risk to the sibs is 50%.</div><div class="half_rhythm">If the father has an intermediate <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, the risk to the sibs of inheriting an HD-causing allele (i.e., &#x02265;36 CAG repeats) can vary depending on a number of factors (see <b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>,</b>
<b>Intermediate alleles</b>).</div></li><li class="half_rhythm"><div class="half_rhythm">A sib who inherits an <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> may or may not develop symptoms of HD.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each child of an individual with HD as a result of heterozygosity for a CAG repeat expansion in <i>HTT</i> has a 50% chance of inheriting the HD-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div><b>Intermediate alleles (IA): 27-35 CAG.</b> Offspring of individuals with an intermediate <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> are at risk for HD because the instability of the CAG repeat as it is passed between generations can result in CAG repeat expansion [<a class="bk_pop" href="#huntington.REF.semaka.2006.283">Semaka et al 2006</a>, <a class="bk_pop" href="#huntington.REF.semaka.2013b.696">Semaka et al 2013b</a>]. Genetic counseling for individuals with intermediate alleles is particularly challenging because of the uncertain clinical outcome for their children [<a class="bk_pop" href="#huntington.REF.semaka.2013a.200">Semaka et al 2013a</a>]. The risk to a child of inheriting a CAG expansion greater than 35 repeats or a "new HD-causing allele" from a parent with an intermediate allele depends on a variety of factors, including the following:</div><ul><li class="half_rhythm"><div class="half_rhythm">The CAG size of the <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Larger CAG sizes are more prone to expansion.</div><div class="half_rhythm">CAG size-specific estimates for repeat instability in sperm have been reported to enable genetic counselors to provide more accurate risk assessment for persons who receive an IA predictive test result [<a class="bk_pop" href="#huntington.REF.hendricks.2009.1375">Hendricks et al 2009</a>, <a class="bk_pop" href="#huntington.REF.semaka.2013b.696">Semaka et al 2013b</a>, <a class="bk_pop" href="#huntington.REF.semaka.2014.303">Semaka &#x00026; Hayden 2014</a>]. While all intermediate CAG repeat sizes were shown to have the possibility of expansion, the probability of expansion increases dramatically with increasing CAG size; approximately 21% of 35 CAG alleles expanded into the disease-associated range. Evidence-based <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> implications for intermediate <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> predictive test results have been published by <a class="bk_pop" href="#huntington.REF.semaka.2014.303">Semaka &#x00026; Hayden [2014]</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>The sex and age of the transmitting parent.</b> Paternally inherited intermediate alleles are more prone to CAG expansion than maternally inherited intermediate alleles; maternal expansions are extremely rare [<a class="bk_pop" href="#huntington.REF.semaka.2015.28">Semaka et al 2015</a>]. Expanded intermediate alleles are preferentially transmitted by males with advanced paternal age.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>The DNA sequence in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration with the CAG expansion.</b> CAG tracts interrupted with CAA and CCG trinucleotides are more stable.</div></li></ul></li><li class="half_rhythm"><div>Each child of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual who is <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for CAG repeat expansion in <i>HTT</i> will inherit an HD-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a CAG expansion in <i>HTT</i>, his or her family members are at risk.</p></div><div id="huntington.Related_Genetic_Counseling_Is"><h3>Related Genetic Counseling Issues</h3><p><b>Predictive testing (i.e., testing of asymptomatic at-risk individuals).</b> Testing of asymptomatic adults at risk for HD is possible. Testing for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the absence of definite symptoms of the disease is predictive testing. Such testing is not useful in accurately predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. However, data reported by <a class="bk_pop" href="#huntington.REF.langbehn.2004.267">Langbehn et al [2004]</a> and <a class="bk_pop" href="#huntington.REF.langbehn.2010.397">Langbehn et al [2010]</a> concerning the likelihood that an individual with a particular size of CAG repeat will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by a specific age may be useful. See <b>Supplementary Tables</b> at <a href="http://cmmt.ubc.ca/legacyfiles/pdf_hayden_supplementary_tables.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">cmmt.ubc.ca</a> (pdf). When testing at-risk individuals for HD, it is helpful to test for the CAG expansion in <i>HTT</i> in an affected family member to confirm that the disorder in the family is HD.</p><ul><li class="half_rhythm"><div>At-risk asymptomatic adult family members may seek testing in order to make personal decisions regarding reproduction, financial matters, and career planning. Asymptomatic individuals at risk may also be eligible to participate in clinical trials. Others may have different motivations including simply the "need to know." Testing of asymptomatic at-risk adult family members usually involves pretest interviews in which the motives for requesting the test, the individual's knowledge of HD, the possible impact of positive and negative test results, and neurologic status are assessed. Those seeking testing should be counseled about problems they may encounter with regard to health, life, and disability insurance coverage, employment and educational discrimination, and changes in social and family interaction. Interestingly, a study has found that genetic testing does not increase the risk for discrimination; perceived genetic discrimination is more likely due to the family history of HD regardless of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> status, rather than due to the specific results of the HD genetic test [<a class="bk_pop" href="#huntington.REF.bombard.2009.b2175">Bombard et al 2009</a>]. Other issues to consider include implications for the at-risk status of other family members [<a class="bk_pop" href="#huntington.REF.bombard.2012.217">Bombard et al 2012</a>]. Depression and suicide ideation are issues to be addressed as part of the predictive testing program for HD [<a class="bk_pop" href="#huntington.REF.robins_wahlin.2000.150">Robins Wahlin et al 2000</a>, <a class="bk_pop" href="#huntington.REF.robins_wahlin.2007.279">Robins Wahlin 2007</a>]. Informed consent should be obtained and records kept confidential. Individuals with a mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> need arrangements for long-term follow up and evaluations.</div></li><li class="half_rhythm"><div>Short-term follow up of the participants in the Canadian Predictive Testing Program has revealed that predictive testing for HD may maintain or even improve the psychological well-being of at-risk individuals even though some had negative experiences. About 10% of the group who were determined to be at decreased risk had serious difficulties adapting to their new status. The major issue for these individuals is the realization that they are facing an unplanned future. Overall, the demand for testing of at-risk asymptomatic adults has been lower than expected in studies conducted before the availability of direct <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. Consistent with use of medical services and genetic testing in general, women are more likely than men to undergo predictive testing for HD [<a class="bk_pop" href="#huntington.REF.taylor.2005.152">Taylor 2005</a>, <a class="bk_pop" href="#huntington.REF.baig.2016.1396">Baig et al 2016</a>].</div></li><li class="half_rhythm"><div>In their study of psychological distress in the partners of asymptomatic individuals who had inherited an HD-causing <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, <a class="bk_pop" href="#huntington.REF.decruyenaere.2005.1077">Decruyenaere et al [2005]</a> found that partners have at least as much distress as the individuals found to have the HD-causing allele yet their grief tends to be "disenfranchised" or not socially recognized.</div></li></ul><p><b>Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals younger than age 18 years)</b></p><ul><li class="half_rhythm"><div>For asymptomatic minors at risk for adult-onset conditions for which early treatment would have no beneficial effect on disease morbidity and mortality, predictive genetic testing is considered inappropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</div></li><li class="half_rhythm"><div>For more information, see the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</div></li><li class="half_rhythm"><div>In a family with an established diagnosis of HD, it is appropriate to consider testing of symptomatic individuals regardless of age.</div></li></ul><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent has an HD-causing <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (&#x0003e;35 CAG repeats) or an intermediate allele (27-35 repeats) non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>Similarly, decisions about testing to determine the genetic status of at-risk asymptomatic family members are best made before pregnancy.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="huntington.Prenatal_Testing_and_Preimpla"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>For fetuses at 50% risk.</b> If the presence of an HD-causing <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has been confirmed in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent or in an affected relative of the at-risk parent, prenatal testing for a pregnancy at increased risk is possible.</p><p><b>Preimplantation genetic diagnosis (PGD)</b> may be an option for families in which an HD-causing <i>HTT</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. Existing PGD exclusion protocols allow for testing of the embryo for couples in an at-risk family who do not wish to undergo presymptomatic testing for the HD-causing allele themselves [<a class="bk_pop" href="#huntington.REF.sermon.2002.591">Sermon et al 2002</a>, <a class="bk_pop" href="#huntington.REF.stern.2002.503">Stern et al 2002</a>, <a class="bk_pop" href="#huntington.REF.moutou.2004.1007">Moutou et al 2004</a>, <a class="bk_pop" href="#huntington.REF.jasper.2006.597">Jasper et al 2006</a>]. Counseling and ethical issues affecting PGD for HD are discussed by <a class="bk_pop" href="#huntington.REF.asscher.2010.30">Asscher &#x00026; Koops [2010]</a>.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing when the testing is being considered for the purpose of pregnancy termination or for early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="huntington.Resources"><h2 id="_huntington_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>European Huntington's Disease Network (EHDN)</b></div><div>Germany</div><div><a href="http://www.ehdn.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ehdn.org</a></div></li><li class="half_rhythm"><div><b>HDBuzz</b></div><div><a href="http://en.hdbuzz.net" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HDBuzz</a></div></li><li class="half_rhythm"><div><b>Huntington Society of Canada</b></div><div>151 Frederick Street</div><div>Suite 400</div><div>Kitchener Ontario N2H 2M2</div><div>Canada</div><div><b>Phone:</b> 800-998-7398 (toll-free); 519-749-7063</div><div><b>Fax:</b> 519-749-8965</div><div><b>Email:</b> info@huntingtonsociety.ca</div><div><a href="http://www.huntingtonsociety.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntingtonsociety.ca</a></div></li><li class="half_rhythm"><div><b>Huntington&#x02019;s Disease Africa</b></div><div><b>Phone:</b> 254746734559</div><div><b>Email:</b> info@hd-africa.org</div><div><a href="https://hd-africa.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hd-africa.org</a></div></li><li class="half_rhythm"><div><b>Huntingtons Association of South Africa (HASA)</b></div><div>South Africa</div><div><a href="https://huntingtons.org.za/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntingtons.org.za</a></div></li><li class="half_rhythm"><div><b>Huntington's Disease Society of America (HDSA)</b></div><div>505 Eighth Avenue</div><div>Suite 902</div><div>New York NY 10018</div><div><b>Phone:</b> 800-345-4372 (toll-free); 212-242-1968</div><div><b>Fax:</b> 212-239-3430</div><div><b>Email:</b> hdsainfo@hdsa.org</div><div><a href="http://www.hdsa.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hdsa.org</a></div></li><li class="half_rhythm"><div><b>International Huntington Association</b></div><div>Netherlands</div><div><b>Email:</b> svein@iha-huntington.org</div><div><a href="http://huntington-disease.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntington-disease.org</a></div></li><li class="half_rhythm"><div><b>La Soci&#x000e9;t&#x000e9; Huntington du Qu&#x000e9;bec (Huntington Society of Quebec)</b></div><div>Montr&#x000e9;al Quebec </div><div>Canada</div><div><b>Phone:</b> 514-282-4272; 877-282-2444; 877-220-0226</div><div><b>Fax:</b> 514-937-0082</div><div><b>Email:</b> shq@huntingtonqc.org</div><div><a href="http://www.huntingtonqc.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntingtonqc.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/huntington-disease-like-syndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Huntington disease</a></div></li><li class="half_rhythm"><div><b>Testing for Huntington Disease: Making an Informed Choice</b></div><div><i>Booklet providing information about Huntington disease and genetic testing</i></div><div>University of Washington Medical Center</div><div>Seattle WA </div><div><a href="http://depts.washington.edu/neurolog/images/neurogenetics/hungtinton.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Testing for Huntington Disease: Making an Informed Choice</a></div></li><li class="half_rhythm"><div><b>Hereditary Disease Foundation</b></div><div>3960 Broadway</div><div>6th Floor</div><div>New York NY 10032</div><div><b>Phone:</b> 212-928-2121</div><div><b>Fax:</b> 212-928-2172</div><div><b>Email:</b> cures@hdfoundation.org</div><div><a href="http://www.hdfoundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hdfoundation.org</a></div></li><li class="half_rhythm"><div><b>European Huntington's Disease Network (EHDN) Registry</b></div><div>Germany</div><div><a href="http://www.euro-hd.net/html/registry/about/description" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EHDN Registry</a></div></li><li class="half_rhythm"><div><b>Huntington Study Group (HSG)</b></div><div>University of Rochester, HSG Administrative Office</div><div>1351 Mount Hope Avenue</div><div>Suite 223</div><div>Rochester NY 14620</div><div><b>Phone:</b> 800-487-7671 (toll-free)</div><div><a href="http://www.huntington-study-group.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.huntington-study-group.org</a></div></li></ul></div><div id="huntington.Molecular_Genetics"><h2 id="_huntington_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="huntington.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Huntington Disease: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1305/table/huntington.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__huntington.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_huntington.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_huntington.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_huntington.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_huntington.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_huntington.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_huntington.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_huntington.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3064" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>HTT</i></a></td><td headers="hd_b_huntington.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3064" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">4p16<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_huntington.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P42858" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Huntingtin</a></td><td headers="hd_b_huntington.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/HTT" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HTT database</a></td><td headers="hd_b_huntington.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=HTT" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HTT</a></td><td headers="hd_b_huntington.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=HTT[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HTT</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="huntington.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="huntington.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Huntington Disease (<a href="/omim/143100,613004" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1305/table/huntington.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__huntington.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/143100" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">143100</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HUNTINGTON DISEASE; HD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613004" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613004</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HUNTINGTIN; HTT</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>HTT</i> (NCBI Gene ID: 3064) encompasses 67 exons and spans nearly 170 kb. <i>HTT</i> is predominantly expressed as a 13.5-kb transcript (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_002111.8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002111.8</a>). Shorter transcripts have been reported to occur in some patients &#x02013; resulting from alternative polyadenylation of the 3'UTR; although these transcripts are not present in transcript databases [<a class="bk_pop" href="#huntington.REF.lin.1993.1541">Lin et al 1993</a>, <a class="bk_pop" href="#huntington.REF.romo.2017.3057">Romo et al 2017</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> contains a <a class="def" href="/books/n/gene/glossary/def-item/trinucleotide-repeat/">trinucleotide repeat</a> (CAG) that is expanded within <i>HTT</i> on at least one <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> of individuals with Huntington disease (HD). For a detailed summary of gene and protein information, see <a href="/books/NBK1305/#huntington.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> The CAG repeat length is highly polymorphic in the population and unaffected alleles have CAG repeat size ranges from nine to 35. The median size <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is 18 CAGs. The most common alleles in all populations contain repeats of 15-20 CAGs in length [<a class="bk_pop" href="#huntington.REF.warby.2009.351">Warby et al 2009</a>]. Intermediate alleles range from 27 to 35 CAG repeats [<a class="bk_pop" href="#huntington.REF.semaka.2013b.696">Semaka et al 2013b</a>].</p><p><b>Pathogenic variants.</b> The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> underlying HD is an expansion of a CAG trinucleotide (or polyglutamine) tract in the first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> of <i>HTT</i>. The CAG repeat length in individuals with HD is 36 or more. Individuals with adult-onset HD usually have a CAG expansion from 40 to 55 whereas those with juvenile onset have CAG expansions greater than 60, often inherited from the father. A well-established inverse correlation between CAG repeat length and age of onset exists. However, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of alleles with a CAG repeat range of 36-39 is reduced.</p><div id="huntington.T.htt_variants_discussed_in_t" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>HTT</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1305/table/huntington.T.htt_variants_discussed_in_t/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__huntington.T.htt_variants_discussed_in_t_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.52_54CAG[9_26]<br />(&#x02264;26 CAG repeats)</td><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln18[9_26]</td><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_4" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_002111.8" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002111<wbr style="display:inline-block"></wbr>​.8</a><br /><a href="/protein/90903231" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002102<wbr style="display:inline-block"></wbr>​.4</a>&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.52CAG[27_35]&#x000a0;<sup>2</sup><br />(27 to 35 CAG repeats)</td><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln18[27_35]</td></tr><tr><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.52CAG[36_39]&#x000a0;<sup>3</sup><br />(36 to 39 CAG repeats)</td><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln18[36_39]</td></tr><tr><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.52CAG[40_?]&#x000a0;<sup>4</sup><br />(&#x02265;40 CAG repeats)</td><td headers="hd_h_huntington.T.htt_variants_discussed_in_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln18[40_?]</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="huntington.TF.5.1"><p class="no_margin">For the reference protein sequence <a href="/protein/90903231" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002102<wbr style="display:inline-block"></wbr>​.4</a> has 3,144 amino acids. The first Gln-residue at position 18 is present in 23 copies; it is designated p.Gln18[23].</p></div></dd><dt>2. </dt><dd><div id="huntington.TF.5.2"><p class="no_margin">Intermediate <i>HTT</i> alleles</p></div></dd><dt>3. </dt><dd><div id="huntington.TF.5.3"><p class="no_margin">Reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> HD-causing <i>HTT</i> alleles</p></div></dd><dt>4. </dt><dd><div id="huntington.TF.5.4"><p class="no_margin">Full-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> HD-causing <i>HTT</i> alleles</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Huntingtin is a protein of 3,144 amino acids (<a href="/protein/90903231" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002102.4</a>) and the structure of the 348-kd HTT protein has recently been resolved employing cryo-electron microscopy [<a class="bk_pop" href="#huntington.REF.guo.2018.117">Guo et al 2018</a>]. Huntingtin is widely expressed with no obvious differences in the regional distribution of the mutated and wild type protein. The polyglutamine tract starts at residue 18 and is followed by a polyproline region. The region downstream of the polyglutamine tract contains a HEAT repeat, a motif consisting of 40 loosely conserved amino acids repeated multiple times in tandem, proposed to be involved in protein-protein interactions [<a class="bk_pop" href="#huntington.REF.palidwor.2009.e1000304">Palidwor et al 2009</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The CAG repeat in <i>HTT</i> is translated into an uninterrupted stretch of glutamine residues that when expanded may have altered structural and biochemical properties.</p></div><div id="huntington.References"><h2 id="_huntington_References_">References</h2><div id="huntington.Published_Guidelines__Consens"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.american_college_of_medical_geneticsamerican_society_of_human_genetics_huntington_disease_genetic_testing_working_group.1998.1243">American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group.  Laboratory guidelines for Huntington disease genetic testing. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">62</span>:1243–7.</span> [<a href="/pmc/articles/PMC1377103/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377103</span></a>] [<a href="/pubmed/9545416" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9545416</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF2">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 10-18-18. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.international_huntington_association_and_the_world_federation_of_neurology_research_group_on_huntingtons_chorea.1994.1533">International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea.  Guidelines for the molecular genetics predictive test in Huntington's disease. <span><span class="ref-journal">Neurology. </span>1994;<span class="ref-vol">44</span>:1533–6.</span> [<a href="/pubmed/8058167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8058167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF4">International Huntington Association and World Federation of Neurology. Guidelines for the molecular genetic predictive test in Huntington's disease. Available <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1049979/pdf/jmedgene00286-0053.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 1994. Accessed 10-18-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF5">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset conditions. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2017. Accessed 10-18-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.world_federation_of_neurology_research_committee_research_group_on_huntingtons_chorea.1989.327">World Federation of Neurology Research Committee Research Group on Huntington's Chorea.  Ethical issues policy statement on Huntington's chorea molecular genetics predictive test. <span><span class="ref-journal">J Neurol Sci. </span>1989;<span class="ref-vol">94</span>:327–32.</span> [<a href="/pubmed/2533250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2533250</span></a>]</div></li></ul></div><div id="huntington.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.anderson.2005.197">Anderson KE, Marshall FJ. Behavioral symptoms associated with Huntington's disease. <span><span class="ref-journal">Adv Neurol. </span>2005;<span class="ref-vol">96</span>:197–208.</span> [<a href="/pubmed/16383221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16383221</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.aronin.2014.1455">Aronin N, DiFiglia M. Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing. <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:1455–61.</span> [<a href="/pubmed/25164989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25164989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.arrasate.2004.805">Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. <span><span class="ref-journal">Nature. </span>2004;<span class="ref-vol">431</span>:805–10.</span> [<a href="/pubmed/15483602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15483602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.asscher.2010.30">Asscher E, Koops B-J. The right not to know and preimplantation genetic diagnosis for Huntington's disease. <span><span class="ref-journal">J Med Ethics. </span>2010;<span class="ref-vol">36</span>:30–3.</span> [<a href="/pubmed/20026690" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20026690</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.aziz.2009.1280">Aziz NA, Jurgens CK, Landwehrmeyer GB, et al.  Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. <span><span class="ref-journal">Neurology. </span>2009;<span class="ref-vol">73</span>:1280–5.</span> [<a href="/pubmed/19776381" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19776381</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bachoudl_vi.2006.303">Bachoud-L&#x000e9;vi AC, Gaura V, Brugieres P, Lefaucheur JP, Boisse MF, Maison P, Baudic S, Ribeiro MJ, Bourdet C, Remy P, Cesaro P, Hantraye P, Peschanski M. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. <span><span class="ref-journal">Lancet Neurol. </span>2006;<span class="ref-vol">5</span>:303–9.</span> [<a href="/pubmed/16545746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16545746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.baig.2016.1396">Baig SS, Strong M, Rosser E, Taverner NV, Glew R, Miedzybrodzka Z, Clarke A, Craufurd D., UK Huntington's Disease Prediction Consortium.  Quarrell OW. 22 years of predictive testing for Huntington's disease: the experience of the UK Huntington's Prediction Consortium. <span><span class="ref-journal">Eur J Hum Genet. </span>2016;<span class="ref-vol">24</span>:1396–402.</span> [<a href="/pmc/articles/PMC5027682/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5027682</span></a>] [<a href="/pubmed/27165004" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27165004</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.baliko.2004.258">Baliko L, Csala B, Czopf J. Suicide in Hungarian Huntington's disease patients. <span><span class="ref-journal">Neuroepidemiology. </span>2004;<span class="ref-vol">23</span>:258–60.</span> [<a href="/pubmed/15316254" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15316254</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.barker.2013.657">Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S, Thornton S, Hurrelbrink C, Armstrong RJ, Tyers P, Smith E, Carpenter A, Piccini P, Tai YF, Brooks DJ, Pavese N, Watts C, Pickard JD, Rosser AE, Dunnett SB, et al.  The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2013;<span class="ref-vol">84</span>:657–65.</span> [<a href="/pmc/articles/PMC3646287/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3646287</span></a>] [<a href="/pubmed/23345280" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23345280</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bates.2015.15005">Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ. Huntington disease. <span><span class="ref-journal">Nat Rev Dis Primers. </span>2015;<span class="ref-vol">1</span>:15005.</span> [<a href="/pubmed/27188817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27188817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bean.2014.e2">Bean L, Bayrak-Toydemir P. American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, 2014 edition: technical standards and guidelines for Huntington disease. <span><span class="ref-journal">Genet Med. </span>2014;<span class="ref-vol">16</span>:e2.</span> [<a href="/pubmed/25356969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25356969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.be_anovi_.2015.807">Be&#x0010d;anovi&#x00107; K, N&#x000f8;rrem&#x000f8;lle A, Neal SJ, Kay C, Collins JA, Arenillas D, Lilja T, Gaudenzi G, Manoharan S, Doty CN, Beck J, Lahiri N, Portales-Casamar E, Warby SC, Connolly C, De Souza RA. REGISTRY Investigators of the European Huntington's Disease Network, Tabrizi SJ, Hermanson O, Langbehn DR, Hayden MR, Wasserman WW, Leavitt BR. A SNP in the HTT promoter alters NF-&#x003ba;B binding and is a bidirectional genetic modifier of Huntington disease. <span><span class="ref-journal">Nat Neurosci. </span>2015;<span class="ref-vol">18</span>:807–16.</span> [<a href="/pubmed/25938884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25938884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bender.2005.36">Bender A, Auer DP, Merl T, Reilmann R, Saemann P, Yassouridis A, Bender J, Weindl A, Dose M, Gasser T, Klopstock T. Creatine supplementation lowers brain glutamate levels in Huntington's disease. <span><span class="ref-journal">J Neurol. </span>2005;<span class="ref-vol">252</span>:36–41.</span> [<a href="/pubmed/15672208" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15672208</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.benjamin.1994.606">Benjamin CM, Adam S, Wiggins S, Theilmann JL, Copley TT, Bloch M, Squitieri F, McKellin W, Cox S, Brown SA, et al.  Proceed with care: direct predictive testing for Huntington disease. <span><span class="ref-journal">Am J Hum Genet. </span>1994;<span class="ref-vol">55</span>:606–17.</span> [<a href="/pmc/articles/PMC1918294/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1918294</span></a>] [<a href="/pubmed/7942838" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7942838</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.biglan.2009.1763">Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS, et al.  Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. <span><span class="ref-journal">Mov Disord. </span>2009;<span class="ref-vol">24</span>:1763–72.</span> [<a href="/pmc/articles/PMC3048804/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3048804</span></a>] [<a href="/pubmed/19562761" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19562761</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bj_rkqvist.2008.1869">Bj&#x000f6;rkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, M&#x000f6;ller T, Tabrizi SJ. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. <span><span class="ref-journal">J Exp Med. </span>2008;<span class="ref-vol">205</span>:1869–77.</span> [<a href="/pmc/articles/PMC2525598/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2525598</span></a>] [<a href="/pubmed/18625748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18625748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.blekher.2006.394">Blekher T, Johnson SA, Marshall J, White K, Hui S, Weaver M, Gray J, Yee R, Stout JC, Beristain X, Wojcieszek J, Foroud T. Saccades in presymptomatic and early stages of Huntington disease. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:394–9.</span> [<a href="/pubmed/16855205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16855205</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bombard.2012.217">Bombard Y, Palin J, Friedman JM, Veenstra G, Creighton S, Bottorff JL, Hayden MR, et al.  Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. <span><span class="ref-journal">Am J Med Genet B Neuropsychiatr Genet. </span>2012;<span class="ref-vol">159B</span>:217–26.</span> [<a href="/pubmed/22231990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22231990</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bombard.2009.b2175">Bombard Y, Veenstra G, Friedman JM, Creighton S, Currie L, Paulsen JS, Bottorff JL, Hayden MR, et al.  Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. <span><span class="ref-journal">BMJ. </span>2009;<span class="ref-vol">338</span>:b2175.</span> [<a href="/pmc/articles/PMC2694258/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2694258</span></a>] [<a href="/pubmed/19509425" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19509425</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bonelli.2007.141">Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. <span><span class="ref-journal">Expert Opin Pharmacother. </span>2007;<span class="ref-vol">8</span>:141–53.</span> [<a href="/pubmed/17257085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17257085</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bonelli.2006.2701">Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. <span><span class="ref-journal">Curr Pharm Des. </span>2006;<span class="ref-vol">12</span>:2701–20.</span> [<a href="/pubmed/16842168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16842168</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bonelli.2004.51">Bonelli RM, Wenning GK, Kapfhammer HP. Huntington's disease: present treatments and future therapeutic modalities. <span><span class="ref-journal">Int Clin Psychopharmacol. </span>2004;<span class="ref-vol">19</span>:51–62.</span> [<a href="/pubmed/15076012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15076012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.borrellpag_s.2006.2642">Borrell-Pag&#x000e8;s M, Zala D, Humbert S, Saudou F. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. <span><span class="ref-journal">Cell Mol Life Sci. </span>2006;<span class="ref-vol">63</span>:2642–60.</span> [<a href="/pubmed/17041811" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17041811</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.boudreau.2009.1053">Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. <span><span class="ref-journal">Mol Ther. </span>2009;<span class="ref-vol">17</span>:1053–63.</span> [<a href="/pmc/articles/PMC2835182/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2835182</span></a>] [<a href="/pubmed/19240687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19240687</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.bourne.2006.41">Bourne C, Clayton C, Murch A, Grant J. Cognitive impairment and behavioural difficulties in patients with Huntington's disease. <span><span class="ref-journal">Nurs Stand. </span>2006;<span class="ref-vol">20</span>:41–4.</span> [<a href="/pubmed/16722121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16722121</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.byrne.2017.601">Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. <span><span class="ref-journal">Lancet Neurol. </span>2017;<span class="ref-vol">16</span>:601–9.</span> [<a href="/pmc/articles/PMC5507767/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5507767</span></a>] [<a href="/pubmed/28601473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28601473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.carroll.2011.2178">Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. <span><span class="ref-journal">Mol Ther. </span>2011;<span class="ref-vol">19</span>:2178–85.</span> [<a href="/pmc/articles/PMC3242664/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3242664</span></a>] [<a href="/pubmed/21971427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21971427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.chao.2017.79">Chao TK, Hu J, Pringsheim T. Risk factors for the onset and progression of Huntington disease. <span><span class="ref-journal">Neurotoxicology. </span>2017;<span class="ref-vol">61</span>:79–99.</span> [<a href="/pubmed/28111121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28111121</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.cicchetti.2014.31">Cicchetti F, Lacroix S, Cisbani G, Valli&#x000e8;res N, Saint-Pierre M, St-Amour I, Tolouei R, Skepper JN, Hauser RA, Mantovani D, Barker RA, Freeman TB. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. <span><span class="ref-journal">Ann Neurol. </span>2014;<span class="ref-vol">76</span>:31–42.</span> [<a href="/pubmed/24798518" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24798518</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.cubo.2016.571">Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Mart&#x000ed;nez-Descalls A, Calvo S, Gil-Polo C, European HD. Network. Clinical manifestations of intermediate allele carriers in Huntington disease. <span><span class="ref-journal">Neurology. </span>2016;<span class="ref-vol">87</span>:571–8.</span> [<a href="/pubmed/27402890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27402890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.cubo.2006.1268">Cubo E, Shannon KM, Tracy D, Jaglin JA, Bernard BA, Wuu J, Leurgans SE. Effect of donepezil on motor and cognitive function in Huntington disease. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:1268–71.</span> [<a href="/pubmed/17030764" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17030764</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.datson.2017.e0171127">Datson NA, Gonz&#x000e1;lez-Barriga A, Kourkouta E, Weij R, van de Giessen J, Mulders S, Kontkanen O, Heikkinen T, Lehtim&#x000e4;ki K, van Deutekom JC. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. <span><span class="ref-journal">PLoS One. </span>2017;<span class="ref-vol">12</span>:e0171127.</span> [<a href="/pmc/articles/PMC5300196/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5300196</span></a>] [<a href="/pubmed/28182673" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28182673</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.davis.2014.209">Davis MY, Keene CD, Jayadev S, Bird T. The co-occurrence of Alzheimer's disease and Huntington's disease: a neuropathological study of 15 elderly Huntington's disease subjects. <span><span class="ref-journal">J Huntingtons Dis. </span>2014;<span class="ref-vol">3</span>:209–17.</span> [<a href="/pubmed/25062863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25062863</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.de_tommaso.2005.280">de Tommaso M, Di Fruscolo O, Sciruicchio V, Specchio N, Cormio C, De Caro MF, Livrea P. Efficacy of levetiracetam in Huntington disease. <span><span class="ref-journal">Clin Neuropharmacol. </span>2005;<span class="ref-vol">28</span>:280–4.</span> [<a href="/pubmed/16340384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16340384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.decruyenaere.2005.1077">Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Demyttenaere K, Dom R, Fryns JP. Partners of mutation-carriers for Huntington's disease: forgotten persons? <span><span class="ref-journal">Eur J Hum Genet. </span>2005;<span class="ref-vol">13</span>:1077–85.</span> [<a href="/pubmed/15999117" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15999117</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.djouss_.2002.1325">Djouss&#x000e9; L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH. Weight loss in early stage of Huntington's disease. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">59</span>:1325–30.</span> [<a href="/pubmed/12427878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12427878</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.dom_nguez.2013.e74131">Dom&#x000ed;nguez D JF, Egan GF, Gray MA, Poudel GR, Churchyard A, Chua P, Stout JC, Georgiou-Karistianis N. Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span>:e74131.</span> [<a href="/pmc/articles/PMC3774648/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3774648</span></a>] [<a href="/pubmed/24066104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24066104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.duan.2014.1366">Duan W, Jiang M, Jin J. Metabolism in HD: still a relevant mechanism? <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:1366–74.</span> [<a href="/pmc/articles/PMC4163071/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4163071</span></a>] [<a href="/pubmed/25124273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25124273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.duff.2007.1341">Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC, et al.  Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. <span><span class="ref-journal">Biol Psychiatry. </span>2007;<span class="ref-vol">62</span>:1341–6.</span> [<a href="/pubmed/17481592" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17481592</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.dufour.2014.797">Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. <span><span class="ref-journal">Mol Ther. </span>2014;<span class="ref-vol">22</span>:797–810.</span> [<a href="/pmc/articles/PMC3982495/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3982495</span></a>] [<a href="/pubmed/24390280" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24390280</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.dunnett.2007.279">Dunnett SB, Rosser AE. Stem cell transplantation for Huntington's disease. <span><span class="ref-journal">Exp Neurol. </span>2007;<span class="ref-vol">203</span>:279–92.</span> [<a href="/pubmed/17208230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17208230</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.eddy.2016.1079">Eddy CM, Parkinson EG, Rickards HE. Changes in mental state and behaviour in Huntington's disease. <span><span class="ref-journal">Lancet Psychiatry. </span>2016;<span class="ref-vol">3</span>:1079–86.</span> [<a href="/pubmed/27663851" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27663851</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.epping.2016.184">Epping EA, Kim JI, Craufurd D, Brashers-Krug TM, Anderson KE, McCusker E, Luther J, Long JD, Paulsen JS., PREDICT-HD Investigators and Coordinators of the Huntington Study Group.  Longitudinal psychiatric symptoms in prodromal Huntington's disease: a decade of data. <span><span class="ref-journal">Am J Psychiatry. </span>2016;<span class="ref-vol">173</span>:184–92.</span> [<a href="/pmc/articles/PMC5465431/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5465431</span></a>] [<a href="/pubmed/26472629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26472629</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.evers.2011.e24308">Evers MM, Pepers BA, van Deutekom JC, Mulders SA, den Dunnen JT, Aartsma-Rus A, van Ommen GJ, van Roon-Mom WM. Targeting several CAG expansion diseases by a single antisense oligonucleotide. <span><span class="ref-journal">PLoS One. </span>2011;<span class="ref-vol">6</span>:e24308.</span> [<a href="/pmc/articles/PMC3164722/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3164722</span></a>] [<a href="/pubmed/21909428" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21909428</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.farrington.2006.279">Farrington M, Wreghitt TG, Lever AM, Dunnett SB, Rosser AE, Barker RA. Neural transplantation in Huntington's disease: the NEST-UK donor tissue microbiological screening program and review of the literature. <span><span class="ref-journal">Cell Transplant. </span>2006;<span class="ref-vol">15</span>:279–94.</span> [<a href="/pubmed/16898222" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16898222</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.fisher.2014.105">Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:105–14.</span> [<a href="/pubmed/24151181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24151181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.furtado.2005.331">Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, Freeman TB, Stoessl AJ. Positron emission tomography after fetal transplantation in Huntington's disease. <span><span class="ref-journal">Ann Neurol. </span>2005;<span class="ref-vol">58</span>:331–7.</span> [<a href="/pubmed/16049929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16049929</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.gaba.2005.1335">Gaba AM, Zhang K, Marder K, Moskowitz CB, Werner P, Boozer CN. Energy balance in early-stage Huntington disease. <span><span class="ref-journal">Am J Clin Nutr. </span>2005;<span class="ref-vol">81</span>:1335–41.</span> [<a href="/pubmed/15941884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15941884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.gagnon.2010.10166">Gagnon KT, Pendergraff HM, Deleavey GF, Swayze EE, Potier P, Randolph J, Roesch EB, Chattopadhyaya J, Damha MJ, Bennett CF, Montaillier C, Lemaitre M, Corey DR. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. <span><span class="ref-journal">Biochemistry. </span>2010;<span class="ref-vol">49</span>:10166–78.</span> [<a href="/pmc/articles/PMC2991413/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2991413</span></a>] [<a href="/pubmed/21028906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21028906</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.galvan.2012.17">Galvan L, Andr&#x000e9; VM, Wang EA, Cepeda C, Levine MS. Functional differences between direct and indirect striatal output pathways in Huntington's disease. <span><span class="ref-journal">J Huntingtons Dis. </span>2012;<span class="ref-vol">1</span>:17–25.</span> [<a href="/pmc/articles/PMC4116084/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4116084</span></a>] [<a href="/pubmed/25063187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25063187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.gambardella.2001.708">Gambardella A, Muglia M, Labate A, Magariello A, Gabriele AL, Mazzei R, Pirritano D, Conforti FL, Patitucci A, Valentino P, Zappia M, Quattrone A. Juvenile Huntington's disease presenting as progressive myoclonic epilepsy. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">57</span>:708–11.</span> [<a href="/pubmed/11524486" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11524486</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.golding.2006.485">Golding CV, Danchaivijitr C, Hodgson TL, Tabrizi SJ, Kennard C. Identification of an oculomotor biomarker of preclinical Huntington disease. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:485–7.</span> [<a href="/pubmed/16625001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16625001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.gonzalezalegre.2006.223">Gonzalez-Alegre P, Afifi AK. Clinical characteristics of childhood-onset (juvenile) Huntington disease: report of 12 patients and review of the literature. <span><span class="ref-journal">J Child Neurol. </span>2006;<span class="ref-vol">21</span>:223–9.</span> [<a href="/pubmed/16901424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16901424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.goodman.2010.882">Goodman AO, Barker RA. How vital is sleep in Huntington's disease? <span><span class="ref-journal">J Neurol. </span>2010;<span class="ref-vol">257</span>:882–97.</span> [<a href="/pubmed/20333394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20333394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.graham.2006.444">Graham RK, Slow EJ, Deng Y, Bissada N, Lu G, Pearson J, Shehadeh J, Leavitt BR, Raymond LA, Hayden MR. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. <span><span class="ref-journal">Neurobiol Dis. </span>2006;<span class="ref-vol">21</span>:444–55.</span> [<a href="/pubmed/16230019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16230019</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.guo.2018.117">Guo Q, Huang Bin, Cheng J, Seefelder M, Engler T, Pfeifer G, Oeckl P, Otto M, Moser F, Maurer M, Pautsch A, Baumeister W, Fern&#x000e1;ndez-Busnadiego R, Kochanek S. The cryo-electron microscopy structure of huntingtin. <span><span class="ref-journal">Nature. </span>2018;<span class="ref-vol">555</span>:117–120.</span> [<a href="/pmc/articles/PMC5837020/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5837020</span></a>] [<a href="/pubmed/29466333" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29466333</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.guo.2012.1379">Guo Z, Rudow G, Pletnikova O, Codispoti KE, Orr BA, Crain BJ, Duan W, Margolis RL, Rosenblatt A, Ross CA, Troncoso JC. Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. <span><span class="ref-journal">Mov Disord. </span>2012;<span class="ref-vol">27</span>:1379–86.</span> [<a href="/pmc/articles/PMC3455126/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3455126</span></a>] [<a href="/pubmed/22975850" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22975850</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.gusella.2009.80">Gusella JF, Macdonald ME. Huntington's disease: the case for genetic modifiers. <span><span class="ref-journal">Genome Med. </span>2009;<span class="ref-vol">1</span>:80.</span> [<a href="/pmc/articles/PMC2768966/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2768966</span></a>] [<a href="/pubmed/19725930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19725930</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.hadzi.2012.1708">Hadzi TC, Hendricks AE, Latourelle JC, Lunetta KL, Cupples LA, Gillis T, Mysore JS, Gusella JF, MacDonald ME, Myers RH, Vonsattel JP. Assessment of cortical and striatal involvement in 523 Huntington disease brains. <span><span class="ref-journal">Neurology. </span>2012;<span class="ref-vol">79</span>:1708–15.</span> [<a href="/pmc/articles/PMC3468776/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3468776</span></a>] [<a href="/pubmed/23035064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23035064</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.heinsen.1999.613">Heinsen H, R&#x000fc;b U, Bauer M, Ulmar G, Bethke B, Sch&#x000fc;ler M, B&#x000f6;cker F, Eisenmenger W, G&#x000f6;tz M, Korr H, Schmitz C. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington's disease. <span><span class="ref-journal">Acta Neuropathol. </span>1999;<span class="ref-vol">97</span>:613–22.</span> [<a href="/pubmed/10378380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10378380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.hendricks.2009.1375">Hendricks AE, Latourelle JC, Lunetta KL, Cupples LA, Wheeler V, Macdonald ME, Gusella JF, Myers RH. Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27-35 CAG). <span><span class="ref-journal">Am J Med Genet A. </span>2009;<span class="ref-vol">149A</span>:1375–81.</span> [<a href="/pmc/articles/PMC2724761/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2724761</span></a>] [<a href="/pubmed/19507258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19507258</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.hersch.2017.594">Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, Rosas HD., Huntington Study Group CREST-E Investigators and Coordinators.  The CREST-E study of creatine for Huntington disease: a randomized controlled trial. <span><span class="ref-journal">Neurology. </span>2017;<span class="ref-vol">89</span>:594–601.</span> [<a href="/pmc/articles/PMC5562960/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5562960</span></a>] [<a href="/pubmed/28701493" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28701493</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.ho.2006.385">Ho AK, Robbins AO, Barker RA. Huntington's disease patients have selective problems with insight. <span><span class="ref-journal">Mov Disord. </span>2006;<span class="ref-vol">21</span>:385–9.</span> [<a href="/pubmed/16211608" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16211608</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.hu.2010.1183">Hu J, Liu J, Corey DR. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. <span><span class="ref-journal">Chem Biol. </span>2010;<span class="ref-vol">17</span>:1183–8.</span> [<a href="/pmc/articles/PMC3021381/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3021381</span></a>] [<a href="/pubmed/21095568" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21095568</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.huntington_study_group.2016.40">Huntington Study Group.  Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. <span><span class="ref-journal">JAMA. </span>2016;<span class="ref-vol">316</span>:40–50.</span> [<a href="/pubmed/27380342" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27380342</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.huntington_study_group.2006.366">Huntington Study Group.  Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">66</span>:366–72.</span> [<a href="/pubmed/16476934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16476934</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.huntington_study_group.1996.136">Huntington Study Group.  Unified Huntington's Disease Rating Scale: reliability and consistency. <span><span class="ref-journal">Mov Disord. </span>1996;<span class="ref-vol">11</span>:136–42.</span> [<a href="/pubmed/8684382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8684382</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.huntington_study_group_domino_investigators.2010.2219">Huntington Study Group DOMINO Investigators.  A futility study of minocycline in Huntington's disease. <span><span class="ref-journal">Mov Disord. </span>2010;<span class="ref-vol">25</span>:2219–24.</span> [<a href="/pubmed/20721920" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20721920</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.huntington_study_group_pharos_investigators.2006.991">Huntington Study Group PHAROS Investigators.  At risk for Huntington disease: the PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. <span><span class="ref-journal">Arch Neurol. </span>2006;<span class="ref-vol">63</span>:991–6.</span> [<a href="/pubmed/16831969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16831969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.jama.2013.255">Jama M, Millson A, Miller CE, Lyon E. Triplet repeat primed PCR simplifies testing for Huntington disease. <span><span class="ref-journal">J Mol Diagn. </span>2013;<span class="ref-vol">15</span>:255–62.</span> [<a href="/pubmed/23414820" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23414820</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.jasper.2006.597">Jasper MJ, Hu DG, Liebelt J, Sherrin D, Watson R, Tremellen KP, Hussey ND. Singleton births after routine preimplantation genetic diagnosis using exclusion testing (D4S43 and D4S126) for Huntington's disease. <span><span class="ref-journal">Fertil Steril. </span>2006;<span class="ref-vol">85</span>:597–602.</span> [<a href="/pubmed/16500325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16500325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.johnson.2018.e717">Johnson EB, Byrne LM, Gregory S, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RA, Zetterberg H, Tabrizi SJ, Scahill RI, Wild EJ., TRACK-HD Study Group.  Neurofilament light protein in blood predicts regional atrophy in Huntington disease. <span><span class="ref-journal">Neurology. </span>2018;<span class="ref-vol">90</span>:e717–23.</span> [<a href="/pmc/articles/PMC5818166/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5818166</span></a>] [<a href="/pubmed/29367444" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29367444</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.kalliolia.2014.1511">Kalliolia E, Silajd&#x0017e;i&#x00107; E, Nambron R, Hill NR, Doshi A, Frost C, Watt H, Hindmarsh P, Bj&#x000f6;rkqvist M, Warner TT. Plasma melatonin is reduced in Huntington's disease. <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:1511–5.</span> [<a href="/pubmed/25164424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25164424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.kay.2016.282">Kay C, Collins JA, Miedzybrodzka Z, Madore SJ, Gordon ES, Gerry N, Davidson M, Slama RA, Hayden MR. Huntington disease reduced penetrance alleles occur at high frequency in the general population. <span><span class="ref-journal">Neurology. </span>2016;<span class="ref-vol">87</span>:282–8.</span> [<a href="/pmc/articles/PMC4955276/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4955276</span></a>] [<a href="/pubmed/27335115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27335115</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.kay.2015.1759">Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR. Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European ancestry. <span><span class="ref-journal">Mol Ther. </span>2015;<span class="ref-vol">23</span>:1759–71.</span> [<a href="/pmc/articles/PMC4817952/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4817952</span></a>] [<a href="/pubmed/26201449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26201449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.kay.2018.346">Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, Greenberg JL, Krause A, Hayden MR. The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. <span><span class="ref-journal">Am J Med Genet B Neuropsychiatr Genet. </span>2018;<span class="ref-vol">177</span>:346–57.</span> [<a href="/pubmed/29460498" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29460498</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.keum.2016.287">Keum JW, Shin A, Gillis T, Mysore JS, Abu Elneel K, Lucente D, Hadzi T, Holmans P, Jones L, Orth M, Kwak S, MacDonald ME, Gusella JF, Lee JM. The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease. <span><span class="ref-journal">Am J Hum Genet. </span>2016;<span class="ref-vol">98</span>:287–98.</span> [<a href="/pmc/articles/PMC4746370/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4746370</span></a>] [<a href="/pubmed/26849111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26849111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.killoran.2014.1404">Killoran A, Biglan KM. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:1404–13.</span> [<a href="/pubmed/25164707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25164707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.killoran.2013.2022">Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, et al.  Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. <span><span class="ref-journal">Neurology. </span>2013;<span class="ref-vol">80</span>:2022–7.</span> [<a href="/pmc/articles/PMC3716408/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3716408</span></a>] [<a href="/pubmed/23624566" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23624566</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.kim.2014.717">Kim EH, Thu DC, Tippett LJ, Oorschot DE, Hogg VM, Roxburgh R, Synek BJ, Waldvogel HJ, Faull RL. Cortical interneuron loss and symptom heterogeneity in Huntington disease. <span><span class="ref-journal">Ann Neurol. </span>2014;<span class="ref-vol">75</span>:717–27.</span> [<a href="/pubmed/24771513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24771513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.kordasiewicz.2012.1031">Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. <span><span class="ref-journal">Neuron. </span>2012;<span class="ref-vol">74</span>:1031–44.</span> [<a href="/pmc/articles/PMC3383626/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3383626</span></a>] [<a href="/pubmed/22726834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22726834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.kuemmerle.1999.842">Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ. Huntington aggregates may not predict neuronal death in Huntington's disease. <span><span class="ref-journal">Ann Neurol. </span>1999;<span class="ref-vol">46</span>:842–9.</span> [<a href="/pubmed/10589536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10589536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.langbehn.2004.267">Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR., International Huntington's Disease Collaborative Group.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. <span><span class="ref-journal">Clin Genet. </span>2004;<span class="ref-vol">65</span>:267–77.</span> [<a href="/pubmed/15025718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15025718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.langbehn.2010.397">Langbehn DR, Hayden MR, Paulsen JS., PREDICT-HD Investigators of the Huntington Study Group.  CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. <span><span class="ref-journal">Am J Med Genet B Neuropsychiatr Genet. </span>2010;<span class="ref-vol">153B</span>:397–408.</span> [<a href="/pmc/articles/PMC3048807/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3048807</span></a>] [<a href="/pubmed/19548255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19548255</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.laplanche.1999.2375">Laplanche JL, Hachimi KH, Durieux I, Thuillet P, Defebvre L, Delasnerie-Laupretre N, Peoc'h K, Foncin JF, Destee A. Prominent psychiatric features and early onset in an inherited prion disease with a new insertional mutation in the prion protein gene. <span><span class="ref-journal">Brain. </span>1999;<span class="ref-vol">122</span>:2375–86.</span> [<a href="/pubmed/10581230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10581230</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.larsson.2006.361">Larsson MU, Luszcz MA, Bui TH, Wahlin TB. Depression and suicidal ideation after predictive testing for Huntington's disease: a two-year follow-up study. <span><span class="ref-journal">J Genet Couns. </span>2006;<span class="ref-vol">15</span>:361–74.</span> [<a href="/pubmed/16967331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16967331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.lee.2012.690">Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS. PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB, REGISTRY study of the European Huntington's Disease Network, Myers RH, HD-MAPS Study Group, MacDonald ME, Gusella JF, COHORT study of the HSG. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. <span><span class="ref-journal">Neurology. </span>2012;<span class="ref-vol">78</span>:690–5.</span> [<a href="/pmc/articles/PMC3306163/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3306163</span></a>] [<a href="/pubmed/22323755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22323755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.lee.2015.516">Lee JM, Wheeler VC, Chao MJ, Vonsattel JP, Pinto RM, Lucente D, Abu-Elneel K, Ramos EM, Mysore JS, Gillis T, MacDonald ME, Gusella JF, Harold D, Stone TC, Escott-Price V, Han J, Vedernikov A, Holmans P, Jones L, Kwak S, Mahmoudi M, Orth M, Landwehrmeyer GB, Paulsen JS, Dorsey ER, Shoulson I, Myers RH. Identification of genetic factors that modify clinical onset of Huntington's disease. <span><span class="ref-journal">Cell. </span>2015;<span class="ref-vol">162</span>:516–26.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.levin.2006.587">Levin BC, Richie KL, Jakupciak JP. Advances in Huntington's disease diagnostics: development of a standard reference material. <span><span class="ref-journal">Expert Rev Mol Diagn. </span>2006;<span class="ref-vol">6</span>:587–96.</span> [<a href="/pubmed/16824032" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16824032</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.li.2006.71">Li JL, Hayden MR, Warby SC, Durr A, Morrison PJ, Nance M, Ross CA, Margolis RL, Rosenblatt A, Squitieri F, Frati L, Gomez-Tortosa E, Garcia CA, Suchowersky O, Klimek ML, Trent RJ, McCusker E, Novelletto A, Frontali M, Paulsen JS, Jones R, Ashizawa T, Lazzarini A, Wheeler VC, Prakash R, Xu G, Djouss&#x000e9; L, Mysore JS, Gillis T, Hakky M, Cupples LA, Saint-Hilaire MH, Cha JH, Hersch SM, Penney JB, Harrison MB, Perlman SL, Zanko A, Abramson RK, Lechich AJ, Duckett A, Marder K, Conneally PM, Gusella JF, MacDonald ME, Myers RH. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. <span><span class="ref-journal">BMC Med Genet. </span>2006;<span class="ref-vol">7</span>:71.</span> [<a href="/pmc/articles/PMC1586197/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1586197</span></a>] [<a href="/pubmed/16914060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16914060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.lin.1993.1541">Lin B, Rommens JM, Graham RK, Kalchman M, MacDonald H, Nasir J, Delaney A, Goldberg YP, Hayden MR. Differential 3' polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. <span><span class="ref-journal">Hum Mol Genet. </span>1993;<span class="ref-vol">2</span>:1541–5.</span> [<a href="/pubmed/7903579" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7903579</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.liu.2015.2691">Liu D, Long JD, Zhang Y, Raymond LA, Marder K, Rosser A, McCusker EA, Mills JA, Paulsen JS., PREDICT-HD Investigators and Coordinators of the Huntington Study Group.  Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. <span><span class="ref-journal">J Neurol. </span>2015;<span class="ref-vol">262</span>:2691–8.</span> [<a href="/pmc/articles/PMC4666501/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4666501</span></a>] [<a href="/pubmed/26410751" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26410751</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.lopez.2014.259">Lopez WO, Nikkhah G, Sch&#x000fc;ltke E, Furlanetti L, Trippel M. Stereotactic planning software for human neurotransplantation: suitability in 22 surgical cases of Huntington's disease. <span><span class="ref-journal">Restor Neurol Neurosci. </span>2014;<span class="ref-vol">32</span>:259–68.</span> [<a href="/pubmed/24164802" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24164802</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.macdonald.1993.971">MacDonald ME. Ambrose CM. Duyao MP. Myers RH. Lin C, Srinidhi L. Barnes G, Taylor SA. James M. Groot N. MacFarlane H. Jenkins B. Anderson MA. Wexler NS. Gusella JF. Bates GP, Baxendale S, Hummerich H, et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. <span><span class="ref-journal">Cell. </span>1993;<span class="ref-vol">72</span>:971–83.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.macleod.2013.221">MacLeod R, Tibben A, Frontali M, Evers-Kiebooms G, Jones A, Martinez-Descales A, Roos RA. Recommendations for the predictive genetic test in Huntington's disease. <span><span class="ref-journal">Clin Genet. </span>2013;<span class="ref-vol">83</span>:221–31.</span> [<a href="/pubmed/22642570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22642570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.majid.2011.2544">Majid DS, Aron AR, Thompson W, Sheldon S, Hamza S, Stoffers D, Holland D, Goldstein J, Corey-Bloom J, Dale AM. Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation. <span><span class="ref-journal">Mov Disord. </span>2011;<span class="ref-vol">26</span>:2544–51.</span> [<a href="/pmc/articles/PMC5615846/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5615846</span></a>] [<a href="/pubmed/21932302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21932302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.marshall.2007.116">Marshall J, White K, Weaver M, Flury Wetherill L, Hui S, Stout JC, Johnson SA, Beristain X, Gray J, Wojcieszek J, Foroud T. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. <span><span class="ref-journal">Arch Neurol. </span>2007;<span class="ref-vol">64</span>:116–21.</span> [<a href="/pubmed/17210818" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17210818</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.martino.2013.650">Martino D, Stamelou M, Bhatia KP. The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2013;<span class="ref-vol">84</span>:650–6.</span> [<a href="/pmc/articles/PMC3646286/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3646286</span></a>] [<a href="/pubmed/22993450" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22993450</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.mcbride.2011.2152">McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, Davidson BL. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. <span><span class="ref-journal">Mol Ther. </span>2011;<span class="ref-vol">19</span>:2152–62.</span> [<a href="/pmc/articles/PMC3242667/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3242667</span></a>] [<a href="/pubmed/22031240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22031240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.mcgarry.2017.152">McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M. Huntington Study Group 2CARE Investigators and Coordinators. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. <span><span class="ref-journal">Neurology. </span>2017;<span class="ref-vol">88</span>:152–9.</span> [<a href="/pmc/articles/PMC5224719/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5224719</span></a>] [<a href="/pubmed/27913695" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27913695</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.mehrabi.2016.67">Mehrabi NF, Waldvogel HJ, Tippett LJ, Hogg VM, Synek BJ, Faull RL. Symptom heterogeneity in Huntington's disease correlates with neuronal degeneration in the cerebral cortex. <span><span class="ref-journal">Neurobiol Dis. </span>2016;<span class="ref-vol">96</span>:67–74.</span> [<a href="/pubmed/27569581" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27569581</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.mestre.2009.cd006456">Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2009;<span class="ref-vol">3</span>:CD006456.</span> [<a href="/pubmed/19588393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19588393</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.michalik.2003.r173">Michalik A, Van Broeckhoven C. Pathogenesis of polyglutamine disorders: aggregation revisited. <span><span class="ref-journal">Hum Mol Genet. </span>2003;<span class="ref-vol">12</span>(Spec No 2):R173–86.</span> [<a href="/pubmed/14504263" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14504263</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.montoya.2006.21">Montoya A, Price BH, Menear M, Lepage M. Brain imaging and cognitive dysfunctions in Huntington's disease. <span><span class="ref-journal">J Psychiatry Neurosci. </span>2006;<span class="ref-vol">31</span>:21–9.</span> [<a href="/pmc/articles/PMC1325063/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1325063</span></a>] [<a href="/pubmed/16496032" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16496032</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.moore.2001.1385">Moore RC, Xiang F, Monaghan J, Han D, Zhang Z, Edstrom L, Anvret M, Prusiner SB. Huntington disease phenocopy is a familial prion disease. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:1385–8.</span> [<a href="/pmc/articles/PMC1235549/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1235549</span></a>] [<a href="/pubmed/11593450" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11593450</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.morton.2013.34">Morton AJ. Circadian and sleep disorder in Huntington's disease. <span><span class="ref-journal">Exp Neurol. </span>2013;<span class="ref-vol">243</span>:34–44.</span> [<a href="/pubmed/23099415" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23099415</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.moss.2017.701">Moss DJH, Pardi&#x000f1;as AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S, Holmans P, Jones L, Tabrizi SJ, et al.  Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <span><span class="ref-journal">Lancet Neurol. </span>2017;<span class="ref-vol">16</span>:701–11.</span> [<a href="/pubmed/28642124" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28642124</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.moutou.2004.1007">Moutou C, Gardes N, Viville S. New tools for preimplantation genetic diagnosis of Huntington's disease and their clinical applications. <span><span class="ref-journal">Eur J Hum Genet. </span>2004;<span class="ref-vol">12</span>:1007–14.</span> [<a href="/pubmed/15470361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15470361</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.nahhas.2005.328">Nahhas FA, Garbern J, Krajewski KM, Roa BB, Feldman GL. Juvenile onset Huntington disease resulting from a very large maternal expansion. <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">137A</span>:328–31.</span> [<a href="/pubmed/16096998" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16096998</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.nance.2001.153">Nance MA, Myers RH. Juvenile onset Huntington's disease--clinical and research perspectives. <span><span class="ref-journal">Ment Retard Dev Disabil Res Rev. </span>2001;<span class="ref-vol">7</span>:153–7.</span> [<a href="/pubmed/11553930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11553930</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.okamoto.2009.1407">Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer D.E, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Chen HS, Tong G, Hayden MR, Lipton SA. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingin. <span><span class="ref-journal">Nat Med. </span>2009;<span class="ref-vol">15</span>:1407–13.</span> [<a href="/pmc/articles/PMC2789858/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2789858</span></a>] [<a href="/pubmed/19915593" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19915593</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.ondo.2007.453">Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2007;<span class="ref-vol">13</span>:453–4.</span> [<a href="/pubmed/17046312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17046312</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.palidwor.2009.e1000304">Palidwor GA, Shcherbinin S, Huska MR, Rasko T, Stelzl U, Arumughan A, Foulle R, Porras P, Sanchez-Pulido L, Wanker EE, Andrade-Navarro MA. Detection of alpha-rod protein repeats using a neural network and application to huntingtin. <span><span class="ref-journal">PLoS Comput Biol. </span>2009;<span class="ref-vol">5</span>:e1000304.</span> [<a href="/pmc/articles/PMC2647740/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2647740</span></a>] [<a href="/pubmed/19282972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19282972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.paulsen.2009.272">Paulsen JS. Functional imaging in Huntington's disease. <span><span class="ref-journal">Exp Neurol. </span>2009;<span class="ref-vol">216</span>:272–7.</span> [<a href="/pmc/articles/PMC3810959/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3810959</span></a>] [<a href="/pubmed/19171138" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19171138</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.paulsen.2006.883">Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E. Preparing for preventive clinical trials: the Predict-HD study. <span><span class="ref-journal">Arch Neurol. </span>2006;<span class="ref-vol">63</span>:883–90.</span> [<a href="/pubmed/16769871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16769871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.paulsen.2005a.725">Paulsen JS, Hoth KF, Nehl C, Stierman L. Critical periods of suicide risk in Huntington's disease. <span><span class="ref-journal">Am J Psychiatry. </span>2005a;<span class="ref-vol">162</span>:725–31.</span> [<a href="/pubmed/15800145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15800145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.paulsen.2008.874">Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, et al.  Detection of Huntington's disease decades before diagnosis: the Predict-HD study. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2008;<span class="ref-vol">79</span>:874–80.</span> [<a href="/pmc/articles/PMC2569211/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2569211</span></a>] [<a href="/pubmed/18096682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18096682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.paulsen.2005b.496">Paulsen JS, Nehl C, Hoth KF, Kanz JE, Benjamin M, Conybeare R, McDowell B, Turner B. Depression and stages of Huntington's disease. <span><span class="ref-journal">J Neuropsychiatry Clin Neurosci. </span>2005b;<span class="ref-vol">17</span>:496–502.</span> [<a href="/pubmed/16387989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16387989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.peinemann.2005.11">Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. <span><span class="ref-journal">J Neurol Sci. </span>2005;<span class="ref-vol">239</span>:11–9.</span> [<a href="/pubmed/16185716" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16185716</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.peters_n.2006.961">Peters&#x000e9;n A, Bj&#x000f6;rkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. <span><span class="ref-journal">Eur J Neurosci. </span>2006;<span class="ref-vol">24</span>:961–7.</span> [<a href="/pubmed/16925587" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16925587</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.peters_n.2005.39">Peters&#x000e9;n A, Gil J, Maat-Schieman ML, Bj&#x000f6;rkqvist M, Tanila H, Ara&#x000fa;jo IM, Smith R, Popovic N, Wierup N, Norl&#x000e9;n P, Li JY, Roos RA, Sundler F, Mulder H, Brundin P. Orexin loss in Huntington's disease. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:39–47.</span> [<a href="/pubmed/15525658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15525658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.pfister.2018.663">Pfister EL, DiNardo N, Mondo E, Borel F, Conroy F, Fraser C, Gernoux G, Han X, Hu D, Johnson E, Kennington L, Liu P, Reid SJ, Sapp E, Vodicka P, Kuchel T, Morton AJ, Howland D, Moser R, Sena-Esteves M, Gao G, Mueller C, DiFiglia M, Aronin N. Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of Huntington's disease. <span><span class="ref-journal">Hum Gene Ther. </span>2018;<span class="ref-vol">29</span>:663–73.</span> [<a href="/pmc/articles/PMC6909722/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6909722</span></a>] [<a href="/pubmed/29207890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29207890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.pfister.2009.226">Pfister EL, Zamore PD. Huntington's disease: silencing a brutal killer. <span><span class="ref-journal">Exp Neurol. </span>2009;<span class="ref-vol">220</span>:226–9.</span> [<a href="/pmc/articles/PMC2805437/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2805437</span></a>] [<a href="/pubmed/19786020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19786020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.phillips.2008.1491">Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. <span><span class="ref-journal">Mov Disord. </span>2008;<span class="ref-vol">23</span>:1491–504.</span> [<a href="/pubmed/18581443" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18581443</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.potter.2004.61">Potter NT, Spector EB, Prior TW. Technical standards and guidelines for Huntington disease testing. <span><span class="ref-journal">Genet Med. </span>2004;<span class="ref-vol">6</span>:61–5.</span> [<a href="/pubmed/14726813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14726813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.pouladi.2009.919">Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Peters&#x000e9;n A, Hayden MR. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. <span><span class="ref-journal">Brain. </span>2009;<span class="ref-vol">132</span>:919–32.</span> [<a href="/pubmed/19224899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19224899</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.pringsheim.2012.1083">Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. <span><span class="ref-journal">Mov Disord. </span>2012;<span class="ref-vol">27</span>:1083–91.</span> [<a href="/pubmed/22692795" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22692795</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.pratley.2000.64">Pratley RE, Salbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with Huntington's disease. <span><span class="ref-journal">Ann Neurol. </span>2000;<span class="ref-vol">47</span>:64–70.</span> [<a href="/pubmed/10632102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10632102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.puri.2005.286">Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:286–92.</span> [<a href="/pubmed/16043801" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16043801</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.quarrell.2013.3">Quarrell OW, Nance MA, Nopoulos P, Paulsen JS, Smith JA, Squitieri F. Managing juvenile Huntington's disease. <span><span class="ref-journal">Neurodegener Dis Manag. </span>2013:3.</span> [<a href="/pmc/articles/PMC3883192/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3883192</span></a>] [<a href="/pubmed/24416077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24416077</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.ravina.2008.1223">Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I, McDermott MP. The relationship between CAG repeat length and clinical progression in Huntington's disease. <span><span class="ref-journal">Mov Disord. </span>2008;<span class="ref-vol">23</span>:1223–7.</span> [<a href="/pubmed/18512767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18512767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.rawlins.2016.144">Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJ, Smeeth L. The prevalence of Huntington's disease. <span><span class="ref-journal">Neuroepidemiology. </span>2016;<span class="ref-vol">46</span>:144–53.</span> [<a href="/pubmed/26824438" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26824438</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.rego.2005.361">Rego AC, de Almeida LP. Molecular targets and therapeutic strategies in Huntington's disease. <span><span class="ref-journal">Curr Drug Targets CNS Neurol Disord. </span>2005;<span class="ref-vol">4</span>:361–81.</span> [<a href="/pubmed/16101555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16101555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.reilmann.2016.1404">Reilmann R. Deutetrabenazine-not a revolution but welcome evolution for treating chorea in Huntington disease. <span><span class="ref-journal">JAMA Neurol. </span>2016;<span class="ref-vol">73</span>:1404–6.</span> [<a href="/pubmed/27749952" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27749952</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.reilmann.2014.1335">Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington's disease based on natural history. <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:1335–41.</span> [<a href="/pubmed/25164527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25164527</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.robbins.2006.e7">Robbins AO, Ho AK, Barker RA. Weight changes in Huntington's disease. <span><span class="ref-journal">Eur J Neurol. </span>2006;<span class="ref-vol">13</span>:e7.</span> [<a href="/pubmed/16879284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16879284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.robins_wahlin.2007.279">Robins Wahlin TB. To know or not to know: a review of behaviour and suicidal ideation in preclinical Huntington's disease. <span><span class="ref-journal">Patient Educ Couns. </span>2007;<span class="ref-vol">65</span>:279–87.</span> [<a href="/pubmed/17000074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17000074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.robins_wahlin.2000.150">Robins Wahlin TB, Backman L, Lundin A, Haegermark A, Winblad B, Anvret M. High suicidal ideation in persons testing for Huntington's disease. <span><span class="ref-journal">Acta Neurol Scand. </span>2000;<span class="ref-vol">102</span>:150–61.</span> [<a href="/pubmed/10987374" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10987374</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.romo.2017.3057">Romo L, Ashar-Patel A, Pfister E, Aronin N. Alterations in mRNA 3' UTR isoform abundance accompany gene expression changes in human Huntington's disease brains. <span><span class="ref-journal">Cell Rep. </span>2017;<span class="ref-vol">20</span>:3057–70.</span> [<a href="/pmc/articles/PMC5625827/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5625827</span></a>] [<a href="/pubmed/28954224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28954224</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.rosenblatt.2007.191">Rosenblatt A. Neuropsychiatry of Huntington's disease. <span><span class="ref-journal">Dialogues Clin Neurosci. </span>2007;<span class="ref-vol">9</span>:191–7.</span> [<a href="/pmc/articles/PMC3181855/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3181855</span></a>] [<a href="/pubmed/17726917" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17726917</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.ross.2014.204">Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ. Huntington disease: natural history, biomarkers and prospects for therapeutics. <span><span class="ref-journal">Nat Rev Neurol. </span>2014;<span class="ref-vol">10</span>:204–16.</span> [<a href="/pubmed/24614516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24614516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.rupp.2010.379">Rupp J, Blekher T, Jackson J, Beristain X, Marshall J, Hui S, Wojcieszek J, Foroud T. Progression in prediagnostic Huntington disease. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2010;<span class="ref-vol">81</span>:379–84.</span> [<a href="/pmc/articles/PMC2872788/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2872788</span></a>] [<a href="/pubmed/19726414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19726414</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.saft.2006.11">Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's disease patients: a case series. <span><span class="ref-journal">BMC Neurol. </span>2006;<span class="ref-vol">6</span>:11.</span> [<a href="/pmc/articles/PMC1413552/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1413552</span></a>] [<a href="/pubmed/16507108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16507108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.scahill.2012.371">Scahill RI, Wild EJ, Tabrizi SJ. Biomarkers for Huntington's disease: an update. <span><span class="ref-journal">Expert Opin Med Diagn. </span>2012;<span class="ref-vol">6</span>:371–5.</span> [<a href="/pubmed/23480802" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23480802</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.schneider.2007.517">Schneider SA, Walker RH, Bhatia KP. The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test. <span><span class="ref-journal">Nat Clin Pract Neurol. </span>2007;<span class="ref-vol">3</span>:517–25.</span> [<a href="/pubmed/17805246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17805246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.semaka.2013a.200">Semaka A, Balneaves LG, Hayden MR. "Grasping the grey": patient understanding and interpretation of an intermediate allele predictive test result for Huntington disease. <span><span class="ref-journal">J Genet Couns. </span>2013a;<span class="ref-vol">22</span>:200–17.</span> [<a href="/pubmed/22903792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22903792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.semaka.2006.283">Semaka A, Creighton S, Warby S, Hayden MR. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. <span><span class="ref-journal">Clin Genet. </span>2006;<span class="ref-vol">70</span>:283–94.</span> [<a href="/pubmed/16965319" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16965319</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.semaka.2014.303">Semaka A, Hayden MR. Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results. <span><span class="ref-journal">Clin Genet. </span>2014;<span class="ref-vol">85</span>:303–11.</span> [<a href="/pubmed/24256063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24256063</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.semaka.2015.28">Semaka A, Kay C, Belfroid RD, Bijlsma EK, Losekoot M, van Langen IM, van Maarle MC, Oosterloo M, Hayden MR, van Belzen MJ. A new mutation for Huntington disease following maternal transmission of an intermediate allele. <span><span class="ref-journal">Eur J Med Genet. </span>2015;<span class="ref-vol">58</span>:28–30.</span> [<a href="/pubmed/25464109" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25464109</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.semaka.2013b.696">Semaka A, Kay C, Doty C, Collins JA, Bijlsma EK, Richards F, Goldberg YP, Hayden MR. CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. <span><span class="ref-journal">J Med Genet. </span>2013b;<span class="ref-vol">50</span>:696–703.</span> [<a href="/pubmed/23896435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23896435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.semaka.2013c.864">Semaka A, Kay C, Doty CN, Collins JA, Tam N, Hayden MR. High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population. <span><span class="ref-journal">Am J Med Genet B Neuropsychiatr Genet. </span>2013c;<span class="ref-vol">162B</span>:864–71.</span> [<a href="/pubmed/24038799" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24038799</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.sermon.2002.591">Sermon K, De Rijcke M, Lissens W, De Vos A, Platteau P, Bonduelle M, Devroey P, Van Steirteghem A, Liebaers I. Preimplantation genetic diagnosis for Huntington's disease with exclusion testing. <span><span class="ref-journal">Eur J Hum Genet. </span>2002;<span class="ref-vol">10</span>:591–8.</span> [<a href="/pubmed/12357329" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12357329</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.siesling.1998.915">Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's disease rating scale: a follow up. <span><span class="ref-journal">Mov Disord. </span>1998;<span class="ref-vol">13</span>:915–9.</span> [<a href="/pubmed/9827615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9827615</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.singhbains.2016.185">Singh-Bains MK, Tippett LJ, Hogg VM, Synek BJ, Roxburgh RH, Waldvogel HJ, Faull RL. Globus pallidus degeneration and clinicopathological features of Huntington disease. <span><span class="ref-journal">Ann Neurol. </span>2016;<span class="ref-vol">80</span>:185–201.</span> [<a href="/pubmed/27255697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27255697</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.sipil_.2015.46">Sipil&#x000e4; JO, Hietala M, Siitonen A, P&#x000e4;iv&#x000e4;rinta M, Majamaa K. Epidemiology of Huntington's disease in Finland. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2015;<span class="ref-vol">21</span>:46–9.</span> [<a href="/pubmed/25466405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25466405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.skirton.2005.167">Skirton H. Huntington disease: a nursing perspective. <span><span class="ref-journal">Medsurg Nurs. </span>2005;<span class="ref-vol">14</span>:167–72.</span> [<a href="/pubmed/16035633" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16035633</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.skotte.2014.e107434">Skotte NH, Southwell AL, &#x000d8;stergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, Hayden MR. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. <span><span class="ref-journal">PLoS One. </span>2014;<span class="ref-vol">9</span>:e107434.</span> [<a href="/pmc/articles/PMC4160241/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4160241</span></a>] [<a href="/pubmed/25207939" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25207939</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.slaughter.2001.306">Slaughter JR, Martens MP, Slaughter KA. Depression and Huntington's disease: prevalence, clinical manifestations, etiology, and treatment. <span><span class="ref-journal">CNS Spectr. </span>2001;<span class="ref-vol">6</span>:306–26.</span> [<a href="/pubmed/16113629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16113629</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.slow.2006.408">Slow EJ, Graham RK, Hayden MR. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. <span><span class="ref-journal">Trends Genet. </span>2006;<span class="ref-vol">22</span>:408–11.</span> [<a href="/pubmed/16806565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16806565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.slow.2005.11402">Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2005;<span class="ref-vol">102</span>:11402–7.</span> [<a href="/pmc/articles/PMC1183566/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1183566</span></a>] [<a href="/pubmed/16076956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16076956</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.southwell.2014.2093">Southwell AL, Skotte NH, Kordasiewicz HB, Ostergaard ME, Watt AT, Carroll JB, Doty CN, Villanueva EB, Petoukhov E, Vaid K, Xie Y, Freier SM, Swayze EE, Seth PP, Bennett CF, Hayden MR. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. <span><span class="ref-journal">Mol Ther. </span>2014;<span class="ref-vol">22</span>:2093–106.</span> [<a href="/pmc/articles/PMC4429695/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4429695</span></a>] [<a href="/pubmed/25101598" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25101598</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.southwell.2015.12166">Southwell AL, Smith SE, Davis TR, Caron NS, Villanueva EB, Xie Y, Collins JA, Ye ML, Sturrock A, Leavitt BR, Schrum AG, Hayden MR. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. <span><span class="ref-journal">Sci Rep. </span>2015;<span class="ref-vol">5</span>:12166.</span> [<a href="/pmc/articles/PMC4502413/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4502413</span></a>] [<a href="/pubmed/26174131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26174131</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.squitieri.2006.208">Squitieri F, Frati L, Ciarmiello A, Lastoria S, Quarrell O. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? <span><span class="ref-journal">Mech Ageing Dev. </span>2006;<span class="ref-vol">127</span>:208–12.</span> [<a href="/pubmed/16274727" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16274727</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.squitieri.2011.1599">Squitieri F, Maglione V, Orobello S, Fornai F. Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells. <span><span class="ref-journal">J Neural Transm. </span>2011;<span class="ref-vol">118</span>:1599–607.</span> [<a href="/pubmed/21519949" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21519949</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.stamler.2013.210">Stamler D, Bradbury M, Brown F. The pharmacokinetics and safety of deuterated-tetrabenazine. <span><span class="ref-journal">Neurology. </span>2013;<span class="ref-vol">80</span> Suppl:210.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.stanek.2014.461">Stanek LM, Sardi SP, Mastis B, Richards AR, Treleaven CM, Taksir T, Misra K, Cheng SH, Shihabuddin LS. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. <span><span class="ref-journal">Hum Gene Ther. </span>2014;<span class="ref-vol">25</span>:461–74.</span> [<a href="/pmc/articles/PMC4028091/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4028091</span></a>] [<a href="/pubmed/24484067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24484067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.stern.2002.503">Stern HJ, Harton GL, Sisson ME, Jones SL, Fallon LA, Thorsell LP, Getlinger ME, Black SH, Schulman JD. Non-disclosing preimplantation genetic diagnosis for Huntington disease. <span><span class="ref-journal">Prenat Diagn. </span>2002;<span class="ref-vol">22</span>:503–7.</span> [<a href="/pubmed/12116316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12116316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.stoy.2000.130">Stoy N, McKay E. Weight loss in Huntington's disease. <span><span class="ref-journal">Ann Neurol. </span>2000;<span class="ref-vol">48</span>:130–1.</span> [<a href="/pubmed/10894233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10894233</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.tabrizi.2009.791">Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC., TRACK-HD investigators.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. <span><span class="ref-journal">Lancet Neurol. </span>2009;<span class="ref-vol">8</span>:791–801.</span> [<a href="/pmc/articles/PMC3725974/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3725974</span></a>] [<a href="/pubmed/19646924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19646924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.tabrizi.2012.42">Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR., TRACK-HD investigators.  Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. <span><span class="ref-journal">Lancet Neurol. </span>2012;<span class="ref-vol">11</span>:42–53.</span> [<a href="/pubmed/22137354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22137354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.tabrizi.2011.31">Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC. TRACK-HD Investigators. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. <span><span class="ref-journal">Lancet Neurol. </span>2011;<span class="ref-vol">10</span>:31–42.</span> [<a href="/pubmed/21130037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21130037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.tabrizi.2013.637">Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR. TRACK-HD Investigators. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. <span><span class="ref-journal">Lancet Neurol. </span>2013;<span class="ref-vol">12</span>:637–49.</span> [<a href="/pubmed/23664844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23664844</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.taylor.2005.152">Taylor S. Gender differences in attitudes among those at risk for Huntington's disease. <span><span class="ref-journal">Genet Test. </span>2005;<span class="ref-vol">9</span>:152–7.</span> [<a href="/pubmed/15943556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15943556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.thu.2010.1094">Thu DC, Oorschot DE, Tippett LJ, Nana AL, Hogg VM, Synek BJ, Luthi-Carter R, Waldvogel HJ, Faull RL. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. <span><span class="ref-journal">Brain. </span>2010;<span class="ref-vol">133</span>(Pt 4):1094–110.</span> [<a href="/pubmed/20375136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20375136</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.timman.2005.215">Timman R, Claus H, Slingerland H, van der Schalk M, Demeulenaere S, Roos RA, Tibben A. Nature and development of Huntington disease in a nursing home population: The Behavior Observation Scale Huntington (BOSH). <span><span class="ref-journal">Cogn Behav Neurol. </span>2005;<span class="ref-vol">18</span>:215–22.</span> [<a href="/pubmed/16340395" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16340395</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.trejo.2004.192">Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Vel&#x000e1;squez L. Assessment of the nutrition status of patients with Huntington's disease. <span><span class="ref-journal">Nutrition. </span>2004;<span class="ref-vol">20</span>:192–6.</span> [<a href="/pubmed/14962685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14962685</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.valenza.2006.165">Valenza M, Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: Is Huntington's disease in the list? <span><span class="ref-journal">Prog Neurobiol. </span>2006;<span class="ref-vol">80</span>:165–76.</span> [<a href="/pubmed/17067733" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17067733</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.van_der_burg.2009.765">van der Burg JM, Bj&#x000f6;rkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. <span><span class="ref-journal">Lancet Neurol. </span>2009;<span class="ref-vol">8</span>:765–74.</span> [<a href="/pubmed/19608102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19608102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.van_der_burg.2017.479">van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA. Body weight is a robust predictor of clinical progression in Huntington disease. <span><span class="ref-journal">Ann Neurol. </span>2017;<span class="ref-vol">82</span>:479–83.</span> [<a href="/pubmed/28779551" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28779551</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.van_duijn.2018">van Duijn E, Vrijmoeth EM, Giltay EJ, Bernhard Landwehrmeyer G, REGISTRY investigators of the European Huntington's Disease Network. Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington's disease gene expansion carriers. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=29253686" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">J Affect Disord.</a> 2018;228:194-204. [<a href="/pubmed/29253686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29253686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.videnovic.2009.471">Videnovic A, Leurgans S, Fan W, Jaglin J, Shannon KM. Daytime somnolence and nocturnal sleep disturbances in Huntington disease. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2009;<span class="ref-vol">15</span>:471–4.</span> [<a href="/pubmed/19041273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19041273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.vonsattel.1998.369">Vonsattel JP, DiFiglia M. Huntington disease. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>1998;<span class="ref-vol">57</span>:369–84.</span> [<a href="/pubmed/9596408" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9596408</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.vonsattel.1985.559">Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>1985;<span class="ref-vol">44</span>:559–77.</span> [<a href="/pubmed/2932539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2932539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.waldvogel.2015.33">Waldvogel HJ, Kim EH, Tippett LJ, Vonsattel JP, Faull RL. The neuropathology of Huntington's disease. <span><span class="ref-journal">Curr Top Behav Neurosci. </span>2015;<span class="ref-vol">22</span>:33–80.</span> [<a href="/pubmed/25300927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25300927</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.wang.2014.231">Wang R, Ross CA, Cai H, Cong WN, Daimon CM, Carlson OD, Egan JM, Siddiqui S, Maudsley S, Martin B. Metabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients. <span><span class="ref-journal">Front Physiol. </span>2014;<span class="ref-vol">5</span>:231.</span> [<a href="/pmc/articles/PMC4066441/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4066441</span></a>] [<a href="/pubmed/25002850" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25002850</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.warby.2009.351">Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. <span><span class="ref-journal">Am J Hum Genet. </span>2009;<span class="ref-vol">84</span>:351–66.</span> [<a href="/pmc/articles/PMC2668007/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2668007</span></a>] [<a href="/pubmed/19249009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19249009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.warby.2011.561">Warby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL, Hayden AR, Kanazawa I, Ross CJ, Hayden MR. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. <span><span class="ref-journal">Eur J Hum Genet. </span>2011;<span class="ref-vol">19</span>:561–6.</span> [<a href="/pmc/articles/PMC3083615/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3083615</span></a>] [<a href="/pubmed/21248742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21248742</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.wexler.2004.3498">Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, Marder K, Penchaszadeh G, Roberts SA, Gayan J, Brocklebank D, Cherny SS, Cardon LR, Gray J, Dlouhy SR, Wiktorski S, Hodes ME, Conneally PM, Penney JB, Gusella J, Cha JH, Irizarry M, Rosas D, Hersch S, Hollingsworth Z, MacDonald M, Young AB, Andresen JM, Housman DE, De Young MM, Bonilla E, Stillings T, Negrette A, Snodgrass SR, Martinez-Jaurrieta MD, Ramos-Arroyo MA, Bickham J, Ramos JS, Marshall F, Shoulson I, Rey GJ, Feigin A, Arnheim N, Acevedo-Cruz A, Acosta L, Alvir J, Fischbeck K, Thompson LM, Young A, Dure L, O'Brien CJ, Paulsen J, Brickman A, Krch D, Peery S, Hogarth P, Higgins DS Jr, Landwehrmeyer B. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2004;<span class="ref-vol">101</span>:3498–503.</span> [<a href="/pmc/articles/PMC373491/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC373491</span></a>] [<a href="/pubmed/14993615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14993615</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.wild.2015.1979">Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR, Zetterberg H, Leavitt BR, Kuhn R, Tabrizi SJ, Macdonald D, Weiss A. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. <span><span class="ref-journal">J Clin Invest. </span>2015;<span class="ref-vol">125</span>:1979–86.</span> [<a href="/pmc/articles/PMC4463213/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4463213</span></a>] [<a href="/pubmed/25844897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25844897</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.wild.2014.1434">Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington's disease: What's in the pipeline? <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:1434–45.</span> [<a href="/pmc/articles/PMC4265300/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4265300</span></a>] [<a href="/pubmed/25155142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25155142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.williams.2009.789">Williams JK, Skirton H, Paulsen JS, Tripp-Reimer T, Jarmon L, McGonigal Kenney M, Birrer E, Hennig BL, Honeyford J. The emotional experiences of family carers in Huntington disease. <span><span class="ref-journal">J Adv Nurs. </span>2009;<span class="ref-vol">65</span>:789–98.</span> [<a href="/pmc/articles/PMC3807601/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3807601</span></a>] [<a href="/pubmed/19228233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19228233</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.xu.2015.1815">Xu M, Wu ZY. Huntington disease in Asia. <span><span class="ref-journal">Chin Med J (Engl). </span>2015;<span class="ref-vol">128</span>:1815–9.</span> [<a href="/pmc/articles/PMC4733723/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4733723</span></a>] [<a href="/pubmed/26112725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26112725</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.yoon.2006.1265">Yoon G, Kramer J, Zanko A, Guzijan M, Lin S, Foster-Barber A, Boxer AL. Speech and language delay are early manifestations of juvenile-onset Huntington disease. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:1265–7.</span> [<a href="/pubmed/17030763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17030763</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="huntington.REF.youssov.2013.1717">Youssov K, Dolbeau G, Maison P, Boiss&#x000e9; M-F, Cleret de Langavant L, Roos RAC, et al.  Unified Huntington's disease rating scale for advanced patients: validation and follow-up study. <span><span class="ref-journal">Mov Disord. </span>2013;<span class="ref-vol">28</span>:1717–23.</span> [<a href="/pmc/articles/PMC5071381/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5071381</span></a>] [<a href="/pubmed/24166899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24166899</span></a>]</div></li></ul></div></div><div id="huntington.Chapter_Notes"><h2 id="_huntington_Chapter_Notes_">Chapter Notes</h2><div id="huntington.Author_Notes"><h3>Author Notes</h3><p>Booklets available through the <a href="https://www.huntingtonsociety.ca/hd-booklets-and-publications/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Huntington Society of Canada</a>:</p><ul><li class="half_rhythm"><div>Loss and Grief: Coping with the Death of a Loved One and with Other Losses Related to Huntington Disease</div></li><li class="half_rhythm"><div>A Physician's Guide to the Management of Huntington Disease (3<sup>rd</sup> edition)</div></li><li class="half_rhythm"><div>Caregiver's Handbook for Advanced Stages of Huntington Disease</div></li><li class="half_rhythm"><div>Juvenile Huntington Disease: A Resource for Families, Health Professionals and Caregivers</div></li><li class="half_rhythm"><div>Understanding Behaviour in Huntington Disease: A Guide for Professionals (3<sup>rd</sup> edition)</div></li><li class="half_rhythm"><div>Personal Perspectives on Genetic Testing for Huntington Disease</div></li><li class="half_rhythm"><div>Understanding Huntington Disease: A Resource for Families</div></li></ul></div><div id="huntington.Author_History"><h3>Author History</h3><p>Nicholas S Caron, PhD (2018-present)<br />Rona K Graham, PhD; University of Sherbrooke, Quebec (2007-2018) <br />Brendan Haigh, PhD; University of British Columbia (1998-2007) <br />Michael R Hayden, MB, ChB, PhD, FRCP(C), FRSC (1998-present) <br />Mahbubul Huq, PhD; University of British Columbia (1998-2007) <br />Simon C Warby, PhD; University of Montreal (2007-2018)<br />Galen EB Wright, PhD (2018-present)</p></div><div id="huntington.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>5 July 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 December 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 April 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 July 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>30 August 2005 (cd) Revision: correction of CAG repeat ranges</div></li><li class="half_rhythm"><div>15 February 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 May 2004 (cd) Revisions</div></li><li class="half_rhythm"><div>23 October 1998 (pb) Review posted live</div></li><li class="half_rhythm"><div>16 May 1998 (mh) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1305</span><span class="label">PMID: <a href="/pubmed/20301482" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301482</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/homocystinuria/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hd-l2/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1305&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1305/?report=reader">PubReader</a></li><li><a href="/books/NBK1305/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1305" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1305" style="display:none" title="Cite this Page"><div class="bk_tt">Caron NS, Wright GEB, Hayden MR. Huntington Disease. 1998 Oct 23 [Updated 2018 Jul 5]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1305/pdf/Bookshelf_NBK1305.pdf">PDF version of this page</a> (658K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#huntington.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#huntington.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#huntington.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#huntington.Genetically_Related_Allelic_D" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#huntington.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#huntington.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#huntington.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#huntington.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#huntington.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#huntington.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#huntington.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3064[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HTT</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1305+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1489006" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1489006" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1489006" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1489006" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301701" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Huntington Disease-Like 2</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Huntington Disease-Like 2<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Anderson DG, Krause A, Margolis RL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26079385" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype.</a><span class="source">[Am J Med Genet B Neuropsychiat...]</span><div class="brieflinkpop offscreen_noflow">Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Krause A, Mitchell C, Essop F, Tager S, Temlett J, Stevanin G, Ross C, Rudnicki D, Margolis R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet B Neuropsychiatr Genet. 2015 Oct; 168(7):573-85. Epub 2015 Jun 16.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301681" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furukawa Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301611" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 17</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinocerebellar Ataxia Type 17<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Toyoshima Y, Onodera O, Yamada M, Tsuji S, Takahashi H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301482" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301482" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041a6d39a66ee2ba6c95b1">Huntington Disease - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Huntington Disease - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:26:53-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CD30DE0401901000000000A4B038F&amp;ncbi_session=CE8CD30DE041A6C1_2635SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1305%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1305&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1305/&amp;ncbi_pagename=Huntington Disease - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CD30DE041A6C1_2635SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>